|Drug, bio-affecting and body treating compositions patents - Monitor Patents|
USPTO Class 424 | Browse by Industry: Previous - Next | All
10/2010 | Recent | 13: May | Apr | Mar | Feb | Jan | 12: Dec | Nov | Oct | Sep | Aug | July | June | May | April | Mar | Feb | Jan | 11: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 10: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | | 09: Dec | Nov | Oct | Sep | Aug | Jl | Jn | May | Apr | Mar | Fb | Jn | | 2008 | 2007 |
Drug, bio-affecting and body treating compositions October categorized by USPTO classification 10/10Below are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application. 10/28/2010 > patent applications in patent subcategories. categorized by USPTO classification
20100272635 - Methods and compositions for diagnosis and/or prognosis in ovarian cancer and lung cancer: Methods and compositions for diagnosis, prognosis and monitoring of ovarian cancer and lung cancer are provided. Assays that detect NHERF-I (or one or more markers related thereto) and NHERF-I-containing complexes are used to assign a diagnosis to a subject being assessed for the presence of ovarian or lung cancer; assign... Agent: Wilson, Sonsini, Goodrich & Rosati
20100272636 - Anti-cd74 immunoconjugates and methods of use: Disclosed are compositions that include anti-CD74 immunoconjugates and optionally a therapeutic and/or diagnostic agent. In preferred embodiments, the immunoconjugates comprise one or more anti-CD74 antibodies or antigen-binding fragments thereof, conjugated to a liposome or micelle. Also disclosed are methods for preparing the immunoconjugates and using the immunoconjugates in diagnostic and... Agent: Immunomedics, Inc.
20100272637 - Compositions emitting positrons and containing inorganic particles, and use thereof in medicine, especially for diagnostic processes: The invention relates to pharmaceutical agents containing a particulate inorganic matrix having a diameter of from 0.1 nm to 100 μm, preferably 1 nm to 10 μm, particularly preferably 1 nm to 1 μm, such as, for example, topaz, (Al2F2)[SiO4], and chiolite, Na[Al3F4], preferably wavellite, Al3(PO4)2(OH,F)2, calcium carbonate, CaCO3, maghemite,... Agent: Millen, White, Zelano & Branigan, P.C.
20100272639 - Polysaccharide nanoparticles: Polysaccharide nanoparticles that are particularly useful in for example drug and agent delivery, tissue-specific targeting, for medical imaging and diagnosis, as well as modifiers of physico-chemical properties. The nanoparticles can be highly-branched glucose homopolymers and can be characterized by a uniform spherical shape. They are monodisperse, hydrophilic and produce low... Agent: Lorelei G. Graham C/o Macleod Dixon LLP
20100272638 - Radiolabelled microparticles, processes for the preparation thereof and the use thereof: The invention relates to microparticles radioactively labelled with the technetium isotope 99m Tc, a process for the preparation thereof and their use for preparing powdered inhalants—suitable for deposition studies, for example—which contain the labelled microparticles as active substances.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation
20100272640 - Monoclonal antibodies against pcbp-1 antigens, and uses therefor: The present invention provides and includes monoclonal antibodies (MoAbs or mAbs) specific or preferentially selective for PCBP-1 antigens, hybridoma lines that secrete these PCBP-1 antibodies or antibody fragments, and the use of such antibodies and antibody fragments to detect PCBP-1 antigens, particularly those expressed by cancer cells. The present invention... Agent: Arnold & Porter LLP Attn:IPDocketing Dept.
20100272641 - Labeled molecular imaging agents, methods of making and methods of use: Imaging agents that comprise labeled substrates of the cystine/glutamate antiporter of cells, whereby the methods of use comprise introducing the labeled agents into cells via the cystine/glutamate antiporter, which are then reduced to a labeled cysteine, and subsequently detected in the cell.... Agent: General Electric Company Global Research
20100272642 - Pet probe having an alkoxy group substituted by fluorine and hydroxy group: Disclosed are: a PET probe compound having an alkoxy group substituted by a fluorine and a hydroxy group, which is useful for the early diagnosis of a conformational disease; a pharmaceutical composition for the treatment and/or prevention of a conformational disease, which comprises the compound; and others.... Agent: Nixon Peabody, LLP
20100272644 - Complexation of fatty acid-conjugated molecules with albumin: The technology described herein is directed to conjugating various therapeutic or functional molecules, such small chemical drugs, peptides, oligonucleotides, isotopes and imaging regents with fatty acids, such as LCFAs. The fatty acid-conjugated molecules are complexed with a human serum albumin protein in vitro.... Agent: Duane Morris LLP - AtlantaIPDepartment
20100272643 - Procaspase 8-mediated disease targeting: The invention provides compositions and method for delivering a therapeutic or diagnostic agent to a disease site in a mammal, the method comprising administering to the mammal a therapeutically or diagnostically effective amount of a pharmaceutical composition, wherein the pharmaceutical composition comprises the therapeutic or diagnostic agent coupled to a... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association
20100272645 - Myocardial perfusion imaging method: A myocardial imaging method that is accomplished by administering one or more adenosine A2A adenosine receptor agonist to a human undergoing myocardial imaging.... Agent: Swiss Tanner, P.C. P.o. Box 1749
20100272646 - Method for inducing lymphoid tissue and modulating intestinal homeostasis: Methods and products for modulating the lymphoid system, especially intestinal homeostasis between intestinal lymphoid tissues and gut flora using ligands for NOD1 and/or CCR6.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.
20100272648 - Methods of identifying improved nmda receptor antagonists: Processes are provided for the identification a compound that is useful to treat or prevent a disorder that lowers the pH in a region of affected tissue comprising assessing the difference in potency, or potency boost, of the compound at physiological pH versus disorder-induced pH in a cell that expresses... Agent: King & Spalding
20100272647 - Receptor: We disclose BACH G-protein coupled receptor (GPCR) polypeptides comprising the amino acid sequence shown in SEQ ID NO. 3 or SEQ ID NO: 5, and homologues, variants and derivatives thereof Nucleic acids capable of encoding BACH polypeptide are also disclosed, in particular, those comprising the nucleic acid sequences shown in... Agent: Kohn & Associates, PLLC
20100272653 - Contrast medium for use in imaging methods: An imaging auxiliary for medical imaging methods contains stabilizer-free superparamagnetic particles such as metal oxides and metals. Preferred are γ-Fe2O3, Fe3O4, MnFe2O4, NiFe2O4, and CoFe2O4 and their mixtures. The auxiliary can additionally contain biologically and pharmacologically active substances such as proteins, antibodies, peptides, or oligonucleotides. The superparamagnetic particles have a... Agent: Gudrun E. Huckett Draudt
20100272649 - Bioactive bone cement and method for its production: A bioactive PMMA (polymethylmethacrylate) bone cement contains a powder component and a reactive monomer liquid, wherein the powder component and the reactive monomer liquid when mixed with one another react with one another and form a polymer-based solid material. The powder component contains particulate polymer powder of polymethylmethacrylates; a radical... Agent: Gudrun E. Huckett Draudt
20100272651 - Method for assessing potential for tumor development and metastasis: The present invention generally provides methods for assessing the potential of tumor formation and/or metastasis using a combination (e.g., a ratio) of the number of circulating tumor cells and the number of circulating cells exhibiting autofluorescence within a selected wavelength region (e.g., red autofluorescence). In one aspect, it is directed... Agent: Nutter Mcclennen & Fish LLP
20100272650 - Semiconductor nanoparticle, and fluorescent labeling substance and molecule/cell imaging method by use thereof: There is provided semiconductor nanoparticles which exhibit enhanced emission efficiency, excellent emission intensity, reduced variation range of emission characteristics among lots and among particles and are excellent in stability and reproducibility. There is further provided a fluorescent labeling agent and molecule/cell imaging method by use of the same. Semiconductor nanoparticles... Agent: Lucas & Mercanti, LLP
20100272652 - Determination of tracers within subjects: The present invention generally relates to the use of tracers, for example, to track a substance that has been administered to a subject. A tracer may be separate from the substance to be administered, or in some cases, the tracer and the substance are chemically bonded to each other. When... Agent: Wolf Greenfield & Sacks, P.C.
20100272654 - Levalbuterol salt: Levalbuterol L-tartrate affords crystals possessing properties desirable for use in a metered dose inhaler.... Agent: Jones Day
20100272655 - Menthylcarboxamides and their use as cooling agents: Described is a new cooling agent represented by Structure I and compositions with known coolers having cooling properties and the application of Structure I in foodstuffs and chewing gum:... Agent: International Flavors & Fragrances Inc.
20100272656 - Flavor molecules: R2 may be selected from a range of 5- and 6-membered heterocyclic rings, and wherein R3 may be H or OH. The compounds give rise to a wide range of flavors, and some are useful as sweetness enhancers, this allowing sweetener content to be reduced while maintaining sweetness. Also disclosed... Agent: Curatolo Sidoti Co., Lpa
20100272657 - Enhanced efficiency of sunscreen compositions: Compositions comprising UV blocking agents, a film forming polymer containing acid groups and a neutralizing agent; compositions and methods for increasing the SPF of a composition by neutralizing at least a portion of the acid groups of the film forming agent with the neutralizing agent.... Agent: Merck Patent Department (k-6-1, 1990)
20100272658 - Enhanced efficiency of sunscreen compositions: Compositions comprising UV blocking agents, a film forming polymer containing acid groups and a neutralizing agent; compositions and methods for increasing the SPF of a composition by neutralizing at least a portion of the acid groups of the film forming agent with the neutralizing agent.... Agent: Merck Patent Department (k-6-1, 1990)
20100272661 - Process for the preparation of inverse latex of acrylamide-based polymers and composition comprising said latex: Process for the preparation of a an inverse latex including from 20% to 70% by weight and preferably from 25% to 50% by weight of a branched or crosslinked polyelectrolyte, characterized in that the polyelectrolyte is a copolymer of 2-acrylamido-2-methylpropanesulfonic acid partially or totally salified with acrylamide and optionally one... Agent: Young & Thompson
20100272659 - Recombinant preparation of selected bromelain fractions: The present invention pertains in general to Bromelain and particularly to the different active compounds contained in this complex mixture of proteins. The present invention provides recombinant expressed cysteine proteases, which are found in Bromelain. It has been found that the method for expression of the recombinant proteins is superior... Agent: Knobbe Martens Olson & Bear LLP
20100272663 - Cosmetic composition including an anhydrous gel and a glyceryl ester: The present invention relates to a cosmetic composition including, in a physiologically acceptable medium: (a) at least 30% by weight of an anhydrous gel having a viscosity of at least 180 000 cP-s at 25° C. which includes at least one oil and at least one copolymer of styrene and... Agent: Young & Thompson
20100272664 - Alpha or beta hydroxy acid adducts of oil: A composition of matter comprising an oil adduct of an oil capable of undergoing an adduct reaction and at least one addition material chosen from an alpha hydroxy acid and a beta hydroxy acid.... Agent: Colgate-palmolive Company
20100272666 - Hair cosmetic composition: A hair cosmetic composition containing the following components (a) and (b) and a hair treatment method in which the hair cosmetic composition is applied to the hair: (a) one or two or more peptides each having the number of amino acid residues being 5 to 50, and having neither a... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.
20100272667 - Shave preparations: A shave preparation comprising water; one or more lipophilic skin conditioning agents; one or more thickening agents; one or more emulsifying agents; and one or more lubricants.... Agent: The Procter & Gamble Company Global Legal Department - Ip
20100272669 - Freeze-dried composition: The invention furthermore relates to a process for the preparation of such freeze-dried compositions, the combination of such freeze-dried compositions in kit-of-parts arrangements together with aqueous solutions and the use of the freeze-dried compositions and of the kit-of-parts combinations for cosmetic and pharmaceutical use, in particular for use as a... Agent: Dilworth & Barrese, LLP
20100272670 - Biodegradable polyanhydrides with natural bioactive molecules: The invention provides polymers that include a biologically active molecule and methods for their use.... Agent: Viksnins Harris & Padys Pllp
20100272668 - Antiviral substance, antiviral fiber, and antiviral fiber structure: The present invention is to provide an antiviral substance effective for inactivating viruses, a fiber product carrying the antiviral substance, and a fiber structure. The antiviral substance comprises a polymer containing a maleic acid component as a monomer unit in its polymer chain, and is effective against an avian influenza... Agent: Oliff & Berridge, PLC
20100272671 - Co-therapy for diabetic conditions: Methods of treating diseases diabetes are disclosed. Methods of modulating elevated fructosamine levels, elevated HbA1c levels, impaired glucose tolerance, and impaired fasting glucose are also disclosed. In some embodiments, methods include co-administration of a biguanide and a bile acid sequestrant. Drug products including a biguanide and bile acid sequestrants in... Agent: Diehl Servilla LLC
20100272672 - Crosslinked hydrogels: The present invention preferably provides for a method of forming and the resulting solid polymer gel composition comprising polyethylene imine and at least one hydrogen bonding polymer. The composition has a greater viscosity than either of the polyethylene imine or the hydrogen bonding polymer alone and is injectable immediately after... Agent: Stroock & Stroock & Lavan, LLP
20100272673 - Ionomeric silicone thermoplastic elastomers: This invention relates to thermoplastic elastomers comprising at least one silicone ionomer. These thermoplastic elastomers may be reprocessed and/or recycled.... Agent: Dow Corning Corporation Co1232
20100272678 - Anti-cancer drugs, and uses relating for malignant melanoma and other cancers: wherein the substituents R1, R2, R3, R6, and R7 are as described in the specification. Other cancers include which may be treated with these compounds include, but are not limited to, malignant melanoma, leukemia, lymphomas (Hodgkins and non-Hodgkins), sarcomas (Ewing's sarcoma), brain tumors, central nervous system (CNS) metastases, gliomas, carcinomas... Agent: Kramer & Amado, P.C.
20100272676 - Chemotherapeutic agents as anti-cancer vaccine adjuvants and therapeutic methods thereof: The present invention relates to an anti-cancer vaccine composition comprising an antigen in association with an effective amount of at least one immunomodulator chemotherapeutic adjuvant eliciting an immune response in a patient and a pharmaceutically acceptable carrier. It also relates to method of preventing tumor growth and reducing tumor growth... Agent: Calfee Halter & Griswold, LLP
20100272679 - Compositions and methods of promoting wound healing: A method of treating a wound in a subject includes administering directly to the wound or an area proximate the wound an amount of SDF-I effective to promote healing of the wound of the subject.... Agent: Tarolli, Sundheim, Covell & Tummino L.L.P.
20100272674 - Hepatitis c virus inhibitors: m
20100272677 - Heterocyclic antiviral compounds: Compounds having the formula I wherein R1, R2, R3, R4, R5a, R5b, R5c and R6 are as defined herein are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication.... Agent: Grant D. Green Patent Law Department, M/s A2-250
20100272675 - Method of administering conjugates: The invention relates to a method of treating a host animal to eliminate pathogenic cells. The method comprises the steps of administering to the host animal a hapten-carrier conjugate, administering to the host animal a TH-I biasing adjuvant, and administering to said host animal a ligand conjugated to a hapten... Agent: Barnes & Thornburg LLP
20100272680 - Piperidinyl cyclic amido antiviral agents: Provided are compounds of Formula (I) and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and their use for treating viral infections mediated by a member of the Flaviviridae family of viruses such as hepatitis C virus (HCV).... Agent: Glaxosmithkline Global Patents
20100272681 - Inhibitors of serine proteases: The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these... Agent: Jonathan P. O''brien, Ph.d. Honigman Miller Schwartz & Cohn LLP
20100272682 - Method for improving pharmacokinetics: The object of the present invention is to elevate the blood levels of a compound of formula I by co-administration with a cytochrome P450 inhibitor.... Agent: Grant D. Green M/s A2-250 Roche Palo Alto L.L.C.
20100272683 - Heterocyclylaminoalkyl substituted benzimidazoles: Heterocyclylaminoalkyl Substituted Benzimidazoles Inhibitors of RSV replication of formula (I): The salts and stereochemically isomeric forms thereof, wherein Q is hydrogen, C1-6alkyl optionally substituted with a heterocycle or Q is C1-6alkyl substituted with both —OR4 and a heterocycle; wherein said heterocycle is oxazolidine, thiazolidine, 1-oxo-thiazolidine, 1,1-dioxothiazolidine, morpholinyl, thiomorpholinyl, 1-oxo-thiomorpholinyl, 1,1-dioxothiomorpholinyl,... Agent: Philip S. Johnson Johnson & Johnson
20100272684 - Hyperbaric treatment in wound healing: This invention relates to methods for treating chronic dermal ulcers using hyperbaric treatment in combination with progenitor cells and chemokine homing factors. Specifically, the invention relates to treatment of chronic wounds resulting from diabetes mellitus using compositions comprising EPC and SDF-1A, under hyperbaric condition to accelerate wound healing.... Agent: Pearl Cohen Zedek Latzer, LLP
20100272688 - Method of treating or retarding the development of blindness: A method for treating an ocular disorder characterized by the defect or absence of a normal gene in the ocular cells of a human or animal subject involves administering to the subject by subretinal injection an effective amount of a recombinant adeno-associated virus carrying a nucleic acid sequence encoding the... Agent: Howson & Howson LLP
20100272687 - Mutant viruses and uses thereof: The present invention provides mutant viruses with a decreased ability to block nuclear transport of mRNA or protein in an infected cell which are attenuated in vivo. The mutant viruses of the present invention may also be capable of triggering the anti-viral systems of normal host cells while remaining sensitive... Agent: Wellstat Management Company. LLC
20100272686 - Oncolytic virus: Malignant tumors that are intrinsically resistant to conventional therapies are significant therapeutic challenges. An embodiment of the present invention provides an oncolytic virus capable of killing target cells, such as a tumor cells. In various embodiments presented herein, the oncolytic virus is armed or encodes a therapeutic polypeptide. In at... Agent: Standley Law Group LLP
20100272685 - Porcine adeno-associated viruses: Porcine tissues were screened for the presence of Adeno-Associated Viruses (AAV). Several AAV sequences were isolated from various porcine tissues, and BLAST analysis confirmed high to low homology with known AAV sequences of different origin. Sequence analysis confirmed the isolation of at least three novel porcine AAV isolates which we... Agent: Ade & Company Inc.
20100272697 - Pancreatic islet cells composition and methods: A composition comprising islet cells and an extracellular matrix component as well as methods of transplanting same are described. Retroperitoneal and subcutaneous islet cells transplants maintain their viability and increased insulin production for prolonged periods of time.... Agent: Pearl Cohen Zedek Latzer, LLP
20100272698 - Yeasts: A yeast cell is provided comprising an artificial nucleic acid construct incorporating a gene associated with yeast cell wall integrity operatively linked to a promoter responsive to conditions characteristic of the digestive tract. Also provided is a method comprising administering to the digestive tract of the subject a yeast cell... Agent: Bose Mckinney & Evans LLP
20100272689 - Protease having algicidal activity, gene encoding the same and algicidal formulation comprising the same: The present invention relates to a protease having algicidal activity, a gene encoding the same and algicidal formulation comprising the same. The protease according to the present invention showed high algicidal activity. Therefore, the protease can be used treatment of red tide in marine region of red tide occurrence.... Agent: Clark & Elbing LLP
20100272701 - Method for producing bactericide or soil conditioner containing bacillus subtilis: The present invention provides a method for producing bactericide or soil conditioner containing Bacillus subtilis which is primarily implementing a mixture of starch, protein, molasses, yeast powder, corn steep liquor, (NH4)2SO4, K2HPO4, MgSO4.7H2O, CaCl2.2H2O and MnSO4.H2O as a culture medium and composed of the steps including choosing bacterial species, preparing... Agent: Liang-jung Chen
20100272690 - Antimicrobial compositions and related methods of use: Antimicrobial compositions comprising one or more compound components generally recognized as safe for human consumption, and related methods of use, such compositions and methods as can be employed in a wide range of agricultural, industrial, building, pharmaceutical and/or personal care products and applications.... Agent: Reinhart Boerner Van Deuren S.c. Attn: Linda Kasulke, Docket Coordinator
20100272699 - Mc-1r, mc-2r, and/or µ opioid receptors stimulation: The invention concerns active substances modulating the expression of the receptors of the products of the POMC gene (MC-IR, MC-2R, and the μ opioid receptor), and possibly modulating the expression of POMC in cutaneous cells, notably to modulate the proliferation and differentiation of epidermal cells in order to re-epithelial, maintain... Agent: Basf Beauty Care Solutions France C/o Connolly Bove Lodge & Hutz LLP
20100272691 - Viruses: Herpes Simplex Viruses are disclosed having single-chain antibodies (scFv) embedded in the viral envelope via fusion with glycoprotein D and with glycoprotein H and L.... Agent: Swanson & Bratschun, L.L.C.
20100272692 - Anticancer composition comprising plant stem cell line derived from taxus cambium or procambium: The present invention relates to a composition for preventing or treating cancer, which contains, as an active ingredient, a Taxus cambium- or procambium-derived cell line; a lysate thereof; an extract thereof; or a culture medium thereof. The cell line, the lysate, the extract, and the culture medium has minimized side... Agent: Edwards Angell Palmer & Dodge LLP
20100272693 - Bone scaffolds, injectable bone repair materials and methods for bone repair: A method of bone repair that includes applying to a subject a composite that comprises at least one calcium phosphate, at least one polyamine polymer material; and a linking structure covalently crosslinking the calcium phosphate to the polyamine polymer material, wherein the linking structure is covalently bonded to the calcium... Agent: Klarquist Sparkman, LLP (ott-nih)
20100272695 - Cell compositions derived from dedifferentiated reprogrammed cells: Methods and cell culture compositions, in particular, pancreatic cell culture methods and compositions, derived from dedifferentiated human reprogrammed pluripotent stem cells, such as, induced pluripotent stem (iPS) cells.... Agent: Knobbe Martens Olson & Bear LLP
20100272694 - Clinic compliant method for banking human placental mesenchymal cells: The present invention relates to a method for processing human placental cell sample, a human placental cell sample obtained according to said method for processing human placental cell sample, a human placental cell bank, a method for banking human placental cells, a method for searching human placental cell sample in... Agent: Chalker Flores, LLP
20100272696 - Human bone-forming cells in the treatment of inflammatory rheumatic diseases: The invention relates to novel therapeutic uses of isolated bone-forming cells, particularly in the treatment of inflammatory rheumatic diseases.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP
20100272700 - Dendritic cell precursors: A method of generating a population of dendritic cell (DC) precursors includes obtaining a population of progenitor cells from a subject and culturing the progenitor cells in a culture medium. The culture medium can include Flt3 ligand and interleukin-6 and be free of granulocyte-macrophage colony-stimulating factor.... Agent: Tarolli, Sundheim, Covell & Tummino L.L.P. Suite 1700
20100272702 - Methods and compositions for treating neuropathies: Methods of treating or preventing axonal degradation in neuropathic diseases in mammals are disclosed. The methods can comprise administering to the mammal an effective amount of an agent that acts by increasing sirtuin activity in diseased and/or injured neurons. The methods can also comprise administering to the mammal an effective... Agent: Zackson Law LLC
20100272703 - Iron fortification mutritional blend: Nutritional blend suitable for fortifying food containing 0.5 mg to 10 mg iron in form of a bioavailable iron source and 50 FTU to 5000 FTU phytase, each per 1 g of the nutritional blend and its use.... Agent: Nixon & Vanderhye, PC
20100272704 - Novel patient subgroups for thrombolysis: A method for treating a stroke patient with thrombolysis, wherein prior to treatment the patient is diagnosed in particular for exhibiting cerebral tissue at risk, a cerebral artery occlusion, and/or an absolute “mismatch volume”.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP
20100272705 - Decontaminant edible product, methods of production and uses thereof: The invention relates to an edible product containing a decontaminant. Particularly, the invention relates to an edible product, for instance, a food-like product, containing an effective amount of activated charcoal to mitigate, substantially reduce or cause the cessation of at least one adverse effect associated with the ingestion of a... Agent: Fanelli Strain & Haag PLLC
20100272714 - Anti-addl antibodies and uses thereof: The present invention relates to antibodies that differentially recognize multi-dimensional conformations of Aβ-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also... Agent: Jane Massey Licata Licata & Tyrrell P.C.
20100272706 - Antivirals: This invention provides methods for inhibiting or treating infection by viruses, in particular pox viruses by modulating a kinase, in particular by inhibiting a host cell kinase, involved in mediating viral infection. Methods to identify, validate, and classify the cellular proteins required by viruses during infection of host cells in... Agent: Wilson, Sonsini, Goodrich & Rosati
20100272709 - Cathepsin l mediated diseases and associated methods and products: This invention relates generally to the treatment of cathepsin or dynamin mediated diseases, such as proteinuria, cancer, and cognitive disease and related products. Diagnostic and other assays are also provided, as well as methods for podocyte cell gene transfer.... Agent: Novak Druce + Quigg LLP (wpb)
20100272711 - Compositions and methods for the treatment and prevention of cardiovascular diseases: The present invention is directed to a pharmaceutical composition, and methods of use thereof, comprising at least one agent which target multiple adenosine receptors (AR) simultaneously in a stoichiometric relationship (i.e. each AR receptor is targeted to an equal extent). Aspects of the present invention relate to pharmaceutical compositions, and... Agent: David S. Resnick
20100272710 - Compositions and methods for treating and preventing aging-associated diseases: Provided herein are novel TXNIP-modulating compounds and methods of use thereof. The TXNIP-modulating compounds may be used to enhance cellular anti-stress defense and prevent stress-induced damage to DNA, proteins and lipids. Therefore, TXNIP-modulating compounds may be used to treat or prevent a wide variety of stress-induced diseases and thus aging.... Agent: John Bianchi
20100272707 - Enzymatic large-scale synthesis of mucin glyconjugates, and immunogenic applications thereof: The present invention relates to mucin glycoconjugates, and to a process of producing mucin glycoconjugates. It relates to the biological, pharmaceutical and medical applications thereof. The invention notably provides mucin glycoconjugates which do not require a protein carrier, such as KHL, to induce an immune response (anti-Tn IgG).... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.
20100272713 - Genetic markers associated with endometriosis and use thereof: The present invention relates to novel genetic markers associated with endometriosis and risk of developing endometriosis, and methods and materials for determining whether a human subject has endometriosis or is at risk of developing endometriosis and the use of such risk information in selectively administering a treatment that at least... Agent: Michael R. Schramm Juneau Biosciences, LLC
20100272712 - Jnk3 as a target for the treatment of angiogenesis-related diseases: Provided herein are methods for treating a subject having or at risk for an angiogenesis-related disorder. The methods include administering to the subject a therapeutically effective amount of an agent that inhibits JNK3 expression, or a therapeutically effective amount of an agent that inhibits JNK3 activity. Disorders that can be... Agent: Alston & Bird LLP
20100272708 - Method for the treatment of type and type iv hypersensitivity: The present application relates to methods for the treatment of eczema and uses of a dairy-derived composition. The treatment involves oral administration of 800 mg/day of a composition comprising TGF-β1, TGF-β2, IGF-1 and 60% (w/w) beta-lactoglobulin derived from whey.... Agent: Ogilvy Renault LLP
20100272715 - Variable antibodies: The present invention discloses inhibitory antibodies against Factor VIII with modified glycosylation, either by enzymatic deglycosylation or by site directed mutagenesis. Said antibodies with modified glycosylation have equal affinity for FVIII but show different inhibiting properties. The use of one or a mixture of said antibodies allow modulation of the... Agent: Nixon & Vanderhye, PC
20100272718 - Antibodies against human nkg2d and uses thereof: The present invention provides isolated anti-human NKG2D monoclonal antibodies useful for therapeutic applications in humans. Typically, the antibodies are fully human or humanized to minimize the risk for immune responses against the antibodies when administered to a patient. Preferred antibodies include human monoclonal antibodies MS and 21F2. As described herein,... Agent: Novo Nordisk, Inc. Intellectual Property Department
20100272716 - Antibodies to vla-1: Antibodies that specifically bind to VLA-1 integrin and methods of using these antibodies to treat immunological disorders in a subject. Also included are crystal structures of complexes formed by VLA-1 antibodies and their ligands, and VLA-1 antagonists and agonists identified by using the structure coordinates of these structures.... Agent: Lando & Anastasi, LLP
20100272717 - Combinations of therapeutic agents for treating cancer: The invention relates to a combination comprising vascular disrupting agent (VDA), such as 5,6-dimethylxanthenone-4-acetic acid or a pharmaceutically acceptable salt, ester or prodrug thereof; and one or more pharmaceutically active agents; pharmaceutical compositions comprising said combination; methods of treatment comprising said combination; processes for making said combination; and a commercial... Agent: Novartis Corporate Intellectual Property
20100272720 - Antibody fusion proteins with a modified fcrn binding site: Disclosed are antibody fusion proteins with a modified FcRn binding site and nucleic acid molecules encoding them. The antibody fusion protein include two polypeptide chains, wherein the first polypeptide chain includes a biologically active molecule linked to at least a portion of an immunoglobulin constant region. The second polypeptide chain... Agent: Goodwin Procter LLP Patent Administrator
20100272719 - Inhibition of neovascularization with a soluble chimeric protein comprising vegf flt-1 and kdr domains: Described herein are novel soluble chimeric fusion proteins comprising amino acid sequences derived from the vascular endothelial growth factor (VEGF) receptors flt-1 and KDR, including domain 4 of KDR. The claimed chimeric fusion proteins antagonize the endothelial cell proliferative and angiogenic activity of VEGF and are useful in the treatment... Agent: The Nath Law Group
20100272721 - Treatment of cancer: Methods of treating cancer using an agent that blocks interaction between TWEAK and its receptor are described.... Agent: Biogen Idec / Finnegan Henderson, LLP
20100272726 - Assays, methods and means: A novel class of hydroxylases is described having the amino acid sequence of SEQ ID NO: 2, 4, 6 and 8, and variants and fragments thereof having HIF hydroxylation activity. The polypeptides of the invention have in particular prolyl hydroxylase activity. An assay method monitors the interaction of the HIF... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP
20100272724 - Binding molecules capable of neutralizing rabies virus and uses thereof: The invention provides binding molecules that specifically bind to rabies virus and are capable of neutralizing the virus. The invention further provides nucleic acid molecules encoding the binding molecules, compositions comprising the binding molecules and methods of identifying or producing the binding molecules. The binding molecules can be used in... Agent: Traskbritt, P.C.
20100272727 - Compound for controlling appetite: Insl5 has been found to be orexigenic, i.e. it increases appetite. Insl5, or a derivative or fragment thereof that retains the ability to bind to the GPR100 receptor, or an Insl5 antibody, are useful in therapy, in particular to treat anorexia nervosa, bulimia, cachexia or wasting disease.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association
20100272728 - Mammalian tumor susceptibility gene products and their uses: The present invention provides methods and compositions for regulating ubiquitination in a cell. In particular, the present invention provides purified polypeptides comprising an ubiquitination-regulating domain. The invention also provides methods of using such polypeptides for screening for agents, for producing antibodies, and for treatment of diseases, e.g., proliferative diseases, neurodegenerative... Agent: Stanford University Office Of Technology Licensing Bozicevic, Field & Francis LLP
20100272729 - Mammalian tumor susceptibility gene products and their uses: The present invention provides methods and compositions for regulating ubiquitination in a cell. In particular, the present invention provides purified polypeptides comprising an ubiquitination-regulating domain. The invention also provides methods of using such polypeptides for screening for agents, for producing antibodies, and for treatment of diseases, e.g., proliferative diseases, neurodegenerative... Agent: Stanford University Office Of Technology Licensing Bozicevic, Field & Francis LLP
20100272725 - Neisserial antigens: The invention provides proteins from Neisseria meningitidis (strains A & B) and from Neisseria gonorrhoeae, including amino acid sequences, the corresponding nucleotide sequences, expression data, and serological data. The proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics.... Agent: Novartis Vaccines And Diagnostics Inc.
20100272723 - Optimized antibodies that target cd19: Antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an FcyR or alters effector function as compared to the parent antibody, and methods of using the antibodies.... Agent: Dorsey & Whitney, LLP Intellectual Property Department
20100272722 - Therapeutic uses of inhibitors of rtp801: The present invention provides novel molecules, compositions, methods and uses for treating microvascular disorders, eye diseases respiratory conditions and hearing disorders based upon inhibition of the RTP801 gene and/or protein.... Agent: Cooper & Dunham, LLP
20100272730 - Antigenic gm-csf peptides and antibodies to gm-csf: Hybridoma lines that secrete human monoclonal antibodies with high binding specificity and biological activity, particularly neutralizing activity against granulocyte-macrophage colony stimulating factor, and methods of generating the hybridoma lines are provided. Target antigens and epitopes are also provided. The antibodies may be used in therapeutic methods, for example in the... Agent: Woodcock Washburn LLP
20100272733 - Antibodies specific to pro-angiogenic isoforms of vascular endothelial growth factor (vegf): The present invention provides antibodies, as well as molecules having at least the antigen-binding portion of an antibody, against agonist pro-angiogenic, pro-permeability, vasodilatory isoforms of VEGF. Disclosed antibodies and antibody fragments are characterized by being capable of binding to and neutralizing pro-angiogenic forms of VEGF while not effecting isoforms of... Agent: Choate, Hall & Stewart LLP
20100272734 - Compositions and methods for increasing muscle growth: This disclosure is in the field of anti-Activin receptor IIB (ActRIIB) antibodies. In particular, it relates to the use of said antibodies for treating muscle disorders, such as muscle wasting due to disease or disuse.... Agent: Novartis Institutes For Biomedical Research, Inc.
20100272732 - Emp2 antibodies and their therapeutic uses: The present invention provides methods and compositions useful in the treatment or prevention of Chlamydia infections and cancer. The methods and compositions inhibit the entry of Chlamydia into a host cell expressing EMP2 by interfering with the interaction between the Chlamydia and EMP2. The methods and compositions target cancers which... Agent: Townsend And Townsend And Crew, LLP
20100272731 - Engineered anti-il-23p19 antibodies: Engineered antibodies to human IL-23p19 are provided, as well as uses thereof, e.g., in treatment of inflammatory, autoimmune, and proliferative disorders.... Agent: Merck C/o Dnax
20100272735 - Method to treat using antagonistic anti-htnfsf13b human antibodies: Human monoclonal antibodies that specifically bind to TNFSF13b polypeptides are disclosed. These antibodies have high affinity for hTNFSF13b (e.g., KD=10−8 M or less), a slow off rate for TNFSF13b dissociation (e.g., Koff=10−3 sec−1 or less) and neutralize TNFSF13b activity in vitro and in vivo. The antibodies of the invention are... Agent: Eli Lilly & Company
20100272736 - Combination antibiotic and antibody therapy for the treatment of pseudomonas aeruginosa infection: The present invention provides improved pharmaceutical compositions and methods of treating or preventing development of bacteremia associated with Pseudomonas aeruginosa infections, where the method comprises administering an antibiotic and an anti-PcrV antibody.... Agent: Townsend And Townsend And Crew, LLP
20100272738 - Anti-ox40l antibodies and methods using same: The invention provides anti-OX40L antibodies, and compositions comprising and methods of using these antibodies.... Agent: Genentech, Inc.
20100272737 - Novel peptides and protein and uses thereof: The present invention relates to a novel gene encoding a protein termed voltage gated calcium channels β subunit anchoring regulator protein (VDCC BARP) or a peptide fragments thereof. The present invention also relates to the use of VDCC BARP in Modulation of voltage gated calcium channels via altering the concentration... Agent: Cohen, Pontani, Lieberman & Pavane LLP
20100272739 - Modulation of gamma-delta t cells to regulate airway hyperresponsiveness: Disclosed is a method for regulation of airway hyperresponsiveness by modulating the action of γδ T cells in a patient. Also disclosed are methods for identifying compounds that regulate airway hyperresponsiveness by modulating γδ T cell action.... Agent: Sheridan Ross PC
20100272740 - Micro- and nanoscale devices for delivery of active fibronolytic agents: Disclosed are devices as may be used to deliver a fibrinolytic agent such as functional tPA to targeted sites. Disclosed devices include micro or nanosized particles as carriers of a fibrinolytic agent and a targeting polypeptide such as antifibrin antibody that specifically binds a component of a blood clot. A... Agent: Dority & Manning, P.A.
20100272741 - Immunity to folate receptors: This document provides methods and materials related to assessing immunity to folate receptors. For example, methods and materials for assessing FRα immunity in a mammal are provided. This document also provides methods and materials related to stimulating immunity to folate receptors.... Agent: Fish & Richardson P.C.
20100272742 - Novel serpentine transmembrane antigens expressed in human cancers and uses thereof: Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STEAP” (Six Transmembrane Epithelial Antigens of the Prostate). Four... Agent: Arnold & Porter LLP (24126) Attn: Sv Docketing Dept.
20100272744 - Omp85 proteins of neisseria gonorrhoeae and neisseria meningitidis, compositions containing same and methods of use thereof: Nucleic acid and amino acid sequences of the Omp85 proteins of N. gonorrhoeae and N. meningitidis, and fragments thereof are useful in vaccine compositions, therapeutic compositions and diagnostic compositions for use in the prevention, treatment and diagnosis of non-symptomatic gonococcal infection or symptomatic disease and non-symptomatic meningococcal infection and symptomatic... Agent: Howson & Howson LLP
20100272743 - Staphylococcus epidermidis nucleic acids and proteins: S epidermidis polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptides and DNA (RNA) for the treatment of infection, particularly infections arising from S epidermidis. Antagonists against the function of such polypeptides... Agent: Glaxosmithkline Global Patents
20100272745 - Vaccines for malaria: The present invention relates to a component for a malaria vaccine comprising: a) an immunogenic particle RTS, S and/or b) an immunogenic particle derived from the CS protein of one or more P. vivax strains and S antigen from Hepatitis B and optionally unfused S antigen, or c) an immunogenic... Agent: Glaxosmithkline Global Patents -us, Uw2220
20100272746 - Lipoparticle comprising a protein and methods of making and using the same: Enveloped virus vectors are described which comprise a cellular virus receptor protein and which are capable of fusing with a cell which comprises a viral envelope protein to which the cellular virus receptor protein is cognate. Enveloped virus vectors comprising a plurality of cellular virus receptor proteins are also described.... Agent: Pepper Hamilton LLP
20100272747 - Polyvalent chimeric rubella virus-based vaccines: A chimeric viral particle that comprises a RV fusion gene is disclosed. The RV fusion gene comprises a first nucleotide sequence encoding a RV that is devoid of RV E1 protein, and a second nucleotide sequence that linked in translation frame to the first nucleotide sequence and encodes a humoral... Agent: Ipc Intellectual Property Connections, Inc.
20100272748 - Vaccine for protection against shigella sonnei disease: Compositions and methods for protecting a susceptible host against an infection of Shigella sonnei are disclosed. Such compositions and methods are useful for protecting the host against bacillary dysentery and shigellosis.... Agent: Nih-ott C/o Sheridan Ross P.C.
20100272750 - Hpv polyepitope constructs and uses thereof: The present invention is directed to HPV polyepitope construct and the use thereoffor the prevention and/or treatment of HPV infection.... Agent: Nixon & Vanderhye, PC
20100272749 - Optimized expression of hpv 58 l1 in yeast: Synthetic DNA molecules encoding the HPV58 L1 protein are provided. Specifically, the present invention provides polynucleotides encoding HPV58 L1 protein, wherein said polynucleotides are codon-optimized for high level expression in a yeast cell. The synthetic molecules may be used to produce HPV58 virus-like particles (VLPs), and to produce vaccines and... Agent: Merck
20100272751 - Truncated l1 protein of human papillomavirus type 18: The invention relates to a truncated L1 protein of the Human Papillomavirus Type 18, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of cervical cancer.... Agent: Fish & Richardson PC
20100272752 - Vaccine for viruses that cause persistent or latent infections: The invention is in general directed to methods and compositions for preventing or treating infections by viruses involved in persistent and/or latent infections. The methods and compositions are directed toward the prevention and treatment of infections caused by viruses such as, for example, herpesviruses, retroviruses, hepatitis viruses, and papillomaviruses, including,... Agent: Townsend And Townsend And Crew, LLP
20100272753 - Recombinant adenovirus vaccines: Recombinant adenovirus vaccines comprising recombinant adenoviruses whose hexon, fiber or protein IX capsid proteins are engineered to include exogenous peptide segments, e.g. vaccines for human papillomavirus (HPV) and malaria.... Agent: Venable LLP
20100272754 - Botulinum toxin administration to treat various conditions: Methods for treating conditions in an animal or human subject. The conditions may be pain, skeletal muscle conditions, smooth muscle conditions, glandular conditions and cosmetic conditions. The methods comprise the step of administering a Clostridium neurotoxin component or Clostridium neurotoxin component encoding DNA to the subject using a needleless syringe.... Agent: Allergan, Inc.
20100272755 - Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom: This invention is in the field of bacterial cultures and specifically relates to the optimization of culture conditions to improve the production of bacterial capsular polysaccharides from Streptococcus strains in fed batch culture and to novel purification methods suitable for production scale purification of bacterial capsular polysaccharides from Streptococcus strains... Agent: Novartis Vaccines And Diagnostics Inc.
20100272756 - Gram positive bacteria preparations for the treatment of diseases comprising an immune dysregulation: This application relates to compositions comprising components prepared from Gram positive bacteria such as Gram positive facultative intracellular bacteria for treatment of disorders comprising an immune dysregulation in humans and animals.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.
20100272757 - Bacillus anthracis protective antigen nucleic acid sequences: The invention relates to improved methods of producing and recovering B. anthracisprotective antigen (PA), especially modified PA which is protease resistant, and to methods of using of these PAs or nucleic acids encoding these PAs for eliciting an immunogenic response in humans, including responses which provide protection against, or reduce... Agent: Klarquist Sparkman, LLP (ott-nih)
20100272758 - Viable non-toxic gram-negative bacteria: The present invention provides non-toxic Gram-negative bacteria. In particular, the present invention provides viable Gram-negative bacteria (e.g., E. coli) substantially lacking lipopolysaccharide (LPS, endotoxin) within the outer membrane. The present invention further provides methods of generating viable non-toxic Gram-negative bacteria and uses thereof. The present invention also provides compositions and... Agent: Frank S. Digiglio Scully, Scott, Murphy & Presser, P.C.
20100272759 - Modified live vaccine of mycoplasma bovis, methods of producing modified live mycoplasma bovis vaccines, combination vaccines and methods of treatment: The present invention relates to new attenuated M. bovis bacteria strains passaged at least 110 times. Moreover, the present invention also provides immunogenic compositions comprising live bacteria of any of those attenuated M. bovis bacteria strain, their manufacture and use for the treatment and prophylaxis of M. bovis infections and... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation
20100272760 - Cancer immunotherapy with a viral antigen-defined, immunomodulator-secreting cell vaccine: A human cell line, which lacks major histocompatibility class I (MHC-I) antigens and major histocompatibility class II (MHC-II) antigens and which has been modified to comprise and express (i) a nucleotide sequence encoding an immunomodulator and (ii) a nucleotide sequence encoding a viral antigen, and a method of inducing or... Agent: Barnes & Thornburg LLP
20100272762 - Freeze-dried coated molded article: The invention relates to freeze-dried molded articles comprising at least one or more active substances and optionally one or more scaffold-forming agents, optionally one or more auxiliary substances, as well as a coating comprising at least one film-forming agent. Furthermore, the invention relates to methods for manufacturing these freeze-dried molded... Agent: Dilworth & Barrese, LLP
20100272761 - Synthesis of lipoamide-grafted high molecular compound and method therefor: The present disclosure provides polymer compounds binding with lipoamide produced by the reaction of the primary amine group of lipoamide with the carboxy group of polysaccharide compounds such as chondroitin sulfates, carboxymethyl celluloses, or hyaluronic acids; functional compounds such as peptides, proteins, growth factors; or drugs; or biocompatible polymers such... Agent: Lowe Hauptman Ham & Berner, LLP
20100272766 - Cosmetic compositions: The present invention relates to pigmented emulsion cosmetic compositions containing emulsifying silicone elastomers that provide a natural appearance to the skin upon application. In particular, these cosmetic compositions are formulated such that agglomeration of the pigment upon application to the skin is minimized.... Agent: The Procter & Gamble Company Global Legal Department - Ip
20100272764 - Microencapsulated compositions and methods for tissue mineralization: The present invention is directed to compositions, products and methods useful for bone and tooth mineralization. The compositions comprise polymer microcapsules containing aqueous salt solutions. The shells of the microcapsules can be semi-permeable or impermeable. Solutions of calcium, fluoride and phosphate salts are particularly useful in the compositions of the... Agent: Rudoler & Derosa LLC Attn: Docket Clerk
20100272763 - Skin external preparation and method of producing the same: A skin external preparation includes an oil-in-water emulsion composition. The emulsion composition contains first oil droplet particles having a minimum particle diameter of 200 nm or more and second oil droplet particles having an average particle diameter of 70 nm or less. The first oil droplet particles contain a first... Agent: Sughrue Mion, PLLC
20100272765 - Stable emulsion and process for preparing the same: The invention relates to a stable emulsion comprising (a) an oil; (b) water; (c) a surfactant; and (d) solid particulate material, wherein an emulsion comprising the oil, water, and the surfactant has a transitional phase inversion point, wherein the stable emulsion contains droplets having a d50 value of below 1... Agent: Akzo Nobel Inc.
20100272767 - Insect controlling bands: Disclosed herein are insect repellant wrist and ankle bands. The bands contain a space within which a substrate that has been impregnated with an insect control repellant can be heated by a heater such as a pouch providing an exothermic chemical reaction. Thus, the bands can efficiently act as repellant... Agent: S.c. Johnson & Son, Inc.
20100272768 - Compositions and methods for cell killing: A solid buffer including one or more ion exchange materials, wherein said solid buffer has a volumetric buffering capacity greater than about 20 mM H+/(L.pH unit) and further wherein, when said material is in an environment capable of transporting H+ ions, said solid buffer is adapted to cause the death... Agent: Rissman Hendricks & Oliverio, LLP
20100272769 - Virus-, bacteria-, and fungi-interacting layered phyllosilicates and methods of use: Layered phyllosilicates are useful for adsorbing and/or binding to and, thereby, inactivating viruses, bacteria and fungi. Accordingly, provided herein are methods of inactivating a virus, bacteria or fungus and methods of treating a viral, bacterial or fungal infection. Methods of delivering a therapeutic agent to a mammalian subject and methods... Agent: Marshall, Gerstein & Borun LLP
20100272770 - Silver nanoparticles with specific surface area and a method for producing them: Silver nanoparticles associated with 20 to 80% by weight of a biocomponent of the genus Lactobacillus, said silver nanoparticles having a ratio of the average particle size to the specific surface area (BET) of from 0.015 to 0.15 nm/m2/g; a method for producing silver nanoparticles, comprising the step of incubating... Agent: Woodcock Washburn LLP
20100272772 - Apparatus, system, and method for creating immunologically enhanced spaces in-vivo: The present invention creates an immunologically protected/enhanced space in viva in a mammal by removing the impact of soluble inhibitors of the mammal's immune system in a defined space within the body. Placing an antigen source within the defined protected space along with a monocyte-containing blood sample from the mammal... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association
20100272771 - Device including bone cage and method for treatment of disease in a subject: Devices, methods, and systems are described for controlling pathogenic condition or disease in a subject. Devices are described that include one or more bone cages. The device including one or more bone cages can be configured to include one or more immunogens and one or more adjuvants. The device including... Agent: The Invention Science Fund Clarence T. Tegreene
20100272774 - Devices and methods for delivery of bioactive agents: Embodiments of the invention include bioactive agent eluting devices. In an embodiment the invention includes a bioactive agent delivery device including a substrate, a hydrophilic polymer disposed on the substrate, and a substantially amorphous bioactive agent disposed on the surface of the hydrophilic polymer. In an embodiment, the invention includes... Agent: Pauly, Devries Smith & Deffner, L.L.C.
20100272775 - Immobilized biologically active entities having a high degree of biological activity following sterilization: The present invention relates to immobilized biologically active entities that retain significant biological activity following sterilization of the immobilized biologically active entities.... Agent: Gore Enterprise Holdings, Inc.
20100272773 - Use of drug polymorphs to achieve controlled drug delivery from a coated medical device: When making a medical device having a drug coating thereon, the drug having a plurality of characteristic morphological forms, the manufacturing process is controlled to produce a predetermined ratio of said morphological forms on the device. The process has application to drug coated balloons.... Agent: Vidas, Arrett & Steinkraus, P.A.
20100272776 - Device including bone cage and method for treatment of disease in a subject: Devices, methods, and systems are described for controlling pathogenic condition or disease in a subject. Devices are described that include one or more bone cages. The device including one or more bone cages can be configured to include one or more immunogens and one or more adjuvants. The device including... Agent: The Invention Science Fund Clarence T. Tegreene
20100272777 - Ocular therapeutic agent delivery devices and methdos for making and using such devices: Ocular implant devices (10, 20, 121) for the delivery of a therapeutic agent to an eye (101, 301) in a controlled and sustained manner. Dual mode and single mode drug delivery devices (10, 20, 121) are illustrated and described. Implants (10, 20) suitable for subconjunctival placement are described. Implants (121,... Agent: Ott-nih C/o Edwards Angell Palmer & Dodge LLP
20100272779 - Progesterone-containing compositions and devices: Progesterone-containing compositions and devices that can maintain opening of a body passageway are described. One aspect of the invention provides a therapeutically effective (e.g., relaxative, anti-oxidative, anti-restenotic, anti-angiogenic, anti-neoplastic, anti-cancerous, anti-precancerous and/or anti-thrombotic) composition or formulation containing progesterone and optionally vitamin E and/or conjugated linoleic acid. Another aspect of the... Agent: Sonnenschein Nath & Rosenthal LLP
20100272778 - Stents having controlled elution: Provided herein is a device comprising: a. stent; b. a plurality of layers on said stent framework to form said device; wherein at least one of said layers comprises a bioabsorbable polymer and at least one of said layers comprises one or more active agents; wherein at least part of... Agent: Wilson, Sonsini, Goodrich & Rosati
20100272780 - Cell lines that produce prostaglandin f2 alpha (pgf2a) and uses thereof: The invention provides cells and cell lines the are genetically modified to express the hCox-2 enzyme, which, in turn, results in the upregulation of prostaglandin F2 alpha (PGF2a) production. The invention also provides encapsulated cell therapy devices containing such cells or cell lines that are capable of delivering PGF2a as... Agent: Mintz Levin Cohn Ferris Glovsky And Popeo, P.C.
20100272781 - Sugar free chewable tablets: This invention relates to chewable tablets containing medicants such as gastrointestinal drugs. More particularly, the invention relates to chewable tablets of medicaments that are sugar free and have reduced calories. Accordingly, the tablets of the invention are suitable for both diabetic and non-diabetic patients.... Agent: Barbara V. Maurer
20100272782 - Acellular tissue matrix compositions for tissue repair: The invention provides tissue repair compositions and methods of making the tissue repair compositions. Also featured are methods of treatment using the tissue repair compositions and articles of manufacture that include the tissue repair compositions.... Agent: Finnegan/kci
20100272783 - Methods of treating infections of the nail: Disclosed herein are compositions and methods of treating or preventing an infection of the nail, claw, or hoof comprising administering to a subject a pharmaceutical composition comprising an N-halogenated or N,N-dihalogenated amine compound of the application.... Agent: Hamilton Desanctis & Cha, LLP
20100272784 - Water-soluble pressure sensitive adhesives: A water-soluble pressure sensitive adhesive comprises a homogeneous blend comprising (a) a polymer selected from the group consisting of N-vinyl caprolactam homopolymers, N-vinyl pyrrolidone copolymers, and mixtures thereof and (b) a non-volatile plasticizer comprising a monohydric or polyhydric alcohol having hydrophilic-lipophilic balance of about 2 to about 10. The N-vinyl... Agent: 3m Innovative Properties Company
20100272787 - Amethod of treating neurodegenerative diseases: This invention provides compositions and methods for treating a subject suffering from a disease or disorder of the nervous system, associated with an inflammatory response. This invention further provides a pharmaceutical composition comprising, inter alia, an agent which increases brain levels of interferon-γ; and an agent which reduces the number... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.
20100272789 - External medicine for treatment or prevention: An external medicine includes an active hydrogen generating agent, which generates active hydrogen by bringing multiple agents into contact, and/ or an active hydrogen generating agent, which activates generated hydrogen molecules.... Agent: Muncy, Geissler, Olds & Lowe, PLLC
20100272790 - Methods of treating skin: A topical composition comprising a lipoic acid, a carnitine, and a carnosine in a suitable vehicle for topical application and a method for treating skin is provided. The present compositions are useful in improving the appearance of aged skin characterized by wrinkles and loss of elasticity. Preferred components include R-lipoic... Agent: Lydia G. Olson
20100272785 - Rna sequence motifs in the context of defined internucleotide linkages inducing specific immune modulatory profiles: Immunostimulatory polymers that contain certain sequence-dependent immunostimulatory RNA motifs and methods for the use of such immunostimulatory polymers and compositions containing such polymers are provided according to the invention. The sequence-dependent immunostimulatory RNA motifs and the polymers incorporating such motifs are potent and selective inducers of TLR7 and the TLR7-associated... Agent: Pharmacia & Upjohn
20100272786 - Vaccine: The invention relates to a replication deficient simian adenoviral vector C7 encoding a protein comprising CS protein from P. falciparum or a fragment thereof, for example as shown in Seq ID No: 1 or Seq ID No: 3. The invention also relates to processes of preparing said viral vector and... Agent: Glaxosmithkline Global Patents -us, Uw2220
20100272788 - Vaccines for malaria: e
20100272791 - Composition having effect on treatment and prevention of dry eye syndrome: Provided is a composition comprising, as an active ingredient, at least one material selected from the group consisting of uridine and derivatives thereof which promote synthesis of hyaluronic acid in animal and human cell and body, and a pharmaceutical preparation containing the same. The composition and pharmaceutical preparation of the... Agent: Cantor Colburn, LLP
20100272792 - Stability additives for dry dha dosage forms: The use of additives to stabilize DHA when compressed into tablets, or filled as a powder into capsules, for oral administration.... Agent: Patent Correspondence Arnall Golden Gregory LLP
20100272793 - Controlled release hydraliazine formulations: The invention is for a method and composition for preparing a controlled release pharmaceutical formulation which can be used to administer Hydralazine hydrochloride over a 24 hours time frame, and for controlled release oral dosage forms of Hydralazine hydrochloride in the form of a tablet and a capsule.... Agent: Myers Wilson P.C.
20100272794 - Pharmaceutical composition of memantine: Present invention provides pharmaceutical composition comprising memantine or a pharmaceutically acceptable salt thereof as well as a method for its production. Also provided are different formulations of the composition their structure and preferred shape.... Agent: Kenyon & Kenyon LLP
20100272795 - Sustained release aminopyridine composition: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of... Agent: Pepper Hamilton LLP
20100272796 - Sustained release aminopyridine composition: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of... Agent: Pepper Hamilton LLP
20100272797 - Pharmaceutical composition for treating hepatitis c virus infection comprising hmg-coa reductase inhibitor and bile acid: Disclosed herein is a pharmaceutical composition for treating hepatitis C virus infection comprising an HMG-CoA reductase inhibitor and bile acid. More specifically, disclosed are a pharmaceutical composition for treating hepatitis C vims infection comprising fluvastatin or a pharmaceutically acceptable salt thereof along with ursodeoxycholic acid and a preparation method thereof.... Agent: Swanson & Bratschun, L.L.C.
20100272798 - Controlled release preparation: A controlled release preparation wherein the release of active ingredient is controlled, which releases an active ingredient for an extended period of time by staying or slowly migrating in the gastrointestinal tract, is provided by means such as capsulating a tablet, granule or fine granule wherein the release of active... Agent: Hamre, Schumann, Mueller & Larson, P.C.
20100272799 - Coating technology to produce a combination solid dosage form: The present invention claims the usage of coating technology to produce multi-segmented pharmaceutical dosage forms for a combination drug therapy. The core matrix containing a drug is coated with drug containing solutions or suspensions. The separation of different drugs in the core and various coating segments prevents drug-drug interaction and... Agent: Hemant N. Joshi
20100272800 - Orally disintegrating olanzapine tablet: According to the present invention an orally disintegrating olanzapine tablet comprising magnesium stearate and sodium stearyl fumarate and one or more phramaceutically acceptable excipient in which the total weight of magnesium stearate and sodium stearyl fumarate is about 0.1 to 5% by weight of the total tablet and wherein the... Agent: Hiscock & Barclay, LLP
20100272801 - Pharmaceutical compositions of amlodipine and valsartan: A single layer pharmaceutical composition comprising active agent(s) amlodipine or a pharmaceutically acceptable salt thereof and valsartan or a pharmaceutically acceptable salt thereof wherein the composition exhibits bioequivalence to the commercially available bilayer tablet dosage form comprising amlodipine besylate and valsartan; when administered to human subject, under the bioequivalence parameters... Agent: Merchant & Gould PC
20100272802 - Compositions comprising strontium and uses thereof in the treatment or prevention of gingivitis, periodontitis, periodontitis as a manifestation of systemic diseases, and necrotizing periodontal diseases: The present invention relates to the use of a pharmaceutical composition comprising at least one strontium salts for the preparation of a medicament for treatment and prevention of gingivitis, periodontitis (aggressive and chronic), periodontitis as a 5 manifestation of systemic diseases and/or necrotizing periodontal diseases. The composition preferably comprises strontium... Agent: Gifford, Krass, Sprinkle,anderson & Citkowski, P.c
20100272806 - Compositions and methods for treating and preventing urolithiasis and conditions associated therewith: Compositions and methods for the treatment of urinary calculi and fragments thereof are provided. Compositions and methods for the prevention and/or treatment of renal and urinary colic caused by urinary calculi or fragments are also provided. Such compositions and methods provide locally effective amounts of diazepam sufficient to prevent formation... Agent: Lucas & Mercanti, LLP
20100272805 - Hydrogels for combinatorial delivery of immune-modulating biomolecules: One embodiment of the current disclosure relates to an immune-modulating composition comprising a hydrogel-forming polymer, an immune-modulating biomolecule operable to recruit or retain an immune cell, and an antigen-related biomolecule. Another embodiment of the current disclosure relates to a method of providing an antigen to an antigen presenting cell in... Agent: Baker Botts L.L.P. Patent Department
20100272804 - Oxidized cationic polysaccharide-based polymer tissue adhesive for medical use: A tissue adhesive formed by reacting an oxidized cationic polysaccharide containing aldehyde groups and amine groups with a multi-arm amine is described. The oxidized cationic polysaccharide-based polymer tissue adhesive may be useful for medical applications including wound closure, supplementing or replacing sutures or staples in internal surgical procedures such as... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center
20100272803 - Repair and regeneration of ocular tissue using postpartum-derived cells: Cells derived from postpartum umbilicus and placenta are disclosed. Pharmaceutical compositions, devices and methods for the regeneration or repair of ocular tissue using the postpartum-derived cells are also disclosed.... Agent: Patton Boggs LLP
20100272809 - Microparticles comprising somatostatin analogues: Disclosed are microparticles comprising a somatostatin analogue embedded in a biocompatible pharmacologically acceptable polymer matrix for a long acting release and pharmaceutical compositions comprising such microparticles.... Agent: Novartis Corporate Intellectual Property
20100272808 - Shell-and-core dosage form approaching zero-order drug release: Drugs are formulated as oral dosage forms for controlled release in which the release rate limiting portion is a shell surrounding the drug-containing core. The shell releases drug from the core by permitting diffusion of the drug from the core. The shell also motes gastric retention of the dosage form... Agent: King & Spalding LLP
20100272807 - Sustained release aminopyridine composition: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of... Agent: Pepper Hamilton LLP
20100272810 - Delivery system for binding and release of growth factors: The present invention provides a polymer delivery system for the in vivo binding and release of growth factors, preferably orthobiologic GF, comprising a hyperbranched polymer having physiologically-acceptable anionic phosphorous groups. The hyperbranched polymer is preferred to be a polyurea with phosphonate anions. This polymer can be cross-linked to form a... Agent: Technology Law, PLLC
20100272815 - Amorphous form of tapentadol hydrochloride: Disclosed herein is a novel and stable amorphous form of tapentadol hydrochloride, a process for the preparation, pharmaceutical compositions, and a method of treating thereof. Disclosed also herein is a stable amorphous co-precipitate of tapentadol hydrochloride with pharmaceutically acceptable excipients, a method for the preparation, pharmaceutical compositions, and a method... Agent: Cantor Colburn, LLP
20100272811 - Complex of trospium and pharmaceutical compositions thereof: The invention is directed to a complex of trospium and saccharin. In one embodiment, the complex is a crystalline form. In another embodiment, the complex is a monohydrate form. The invention also encompasses methods of preparing the the saccharin complex of trospium and to pharmaceutical compositions thereof.... Agent: Elmore Patent Law Group, PC
20100272814 - Method and means for producing bronchorelaxation: A method of producing bronchorelaxation in the lungs of a human or animal affected by airway obstruction comprises administration of a pharmacologically effective amount to the body or to the intestine of said human or animal of an agent capable of binding mercury in elemental, ionic and/or organic form present... Agent: Dickstein Shapiro LLP
20100272813 - Nanoparticle-mediated treatment for inflammatory diseases: The present invention provides nanoparticles for treatment of inflammatory diseases. The nanoparticles preferably comprise chitosan and a siRNA targeting a mRNA encoding a pro-inflammatory cytokine, such as e.g. tnf-alfa. A preferred route of administration of the nanoparticles is by injection intraperitoneally.... Agent: Knobbe Martens Olson & Bear LLP
20100272812 - Rgd-modified alginate microparticles as a drug release system: The object of the present invention is to provide particles of a polymeric material containing cells therein, wherein said particles have a strength that is substantially greater than the microcapsules known in the state of the art. Said strength is achieved by means of functionalizing the polymeric material forming the... Agent: Moore & Van Allen PLLC
20100272817 - Compositions and methods for treating atherosclerosis: Reverse peptides and mimetics of a mammalian serum amyloid A isoform 2.1 (SAA2.1) domain or a portion thereof and compositions and pharmaceutical compositions thereof are provided that enhance the effect on macrophage cholesterol ester hydrolase activity. Methods of using these reverse peptides, mimetics thereof and compositions in the treatment and/or... Agent: Licata & Tyrrell P.C.
20100272816 - Microcapsules comprising liver cells and erythropoietin, methods for preparing said microcapsules and methods for treating a patient comprising applying said microcapsules to the patient: Microcapsules containing a capsule shell encapsulating a suspension of a therapeutically effective amount of liver cells in physical contact to a liver cell stimulating amount of erythropoietin.... Agent: Ostrolenk Faber Gerb & Soffen
20100272818 - Compositions and methods comprising terpenes or terpene mixtures selected from thymol, eugenol, geraniol, citral, and l-carvone: The present invention relates to compositions comprising terpenes which are particularly suitable for treating plant infections, to methods of making such compositions, and to methods of using them. The present invention also relates to compositions comprising terpenes and hollow glucan particles or cell wall particles and methods for preparing such... Agent: Ballard Spahr LLP
20100272819 - Production of cellulose nanoparticles: The present invention relates to novel nanoparticles based on cellulose and a process for producing them and their use.... Agent: The Dow Chemical Company
20100272820 - Preparation method of sustained-release microcapsules having good initial burst inhibiting property and the microcapsules thereby: Disclosed is a method for preparing a longer sustained-release formulation containing bioactive substances. More particularly, the present invention provides a method for preparing longer sustained-release microcapsules comprising: adding an emulsion including bioactive substances, biocompatible polymer and polyvinylpyrrolidone to an aqueous solution.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.
20100272821 - Cosmetic composition for external administration in spray form: Cosmetic composition for external administration in spray form. The present invention refers to a cosmetic composition for external administration in spray form and to a production process of this cosmetic composition containing at least an active compound, a continuous external dispersing phase (natural mineral spring water and/or wine), sodium polyphosphate,... Agent: Sturm & Fix LLP
20100272822 - Nanocell drug delivery system: Nanocells allow the sequential delivery of two different therapeutic agents with different modes of action or different pharmacokinetics. A nanocell is formed by encapsulating a nanocore with a first agent inside a lipid vesicle containing a second agent. The agent in the outer lipid compartment is released first and may... Agent: Sutherland Asbill & Brennan LLP
20100272823 - Pulmonary delivery particles comprising water insoluble or crystalline active agents: A pulmonary delivery medicament comprises a plurality of particulates, the particulates comprising a structural matrix and a water insoluble and/or crystalline active agent. The particulates have a geometric diameter of 0.5 to 50 μm. The water insoluble active agent can be a fungicide, antibiotic, budesonide. A method of making the... Agent: Novartis Corporate Intellectual Property
20100272824 - Compositions and methods for preventing and monitoring disease: Gene expression patterns were analyzed that identified multiple genes associated with radiation enhanced colon carcinogenesis. Some of the genes modulated by radiation exposure may be involved in up-regulating the Wnt/β-catenin signaling pathway and promote colon carcinogenesis. Consumption of a fish oil/pectin diet caused a general down-regulation of genes encoding proteins... Agent: Medlen & Carroll, LLP
20100272825 - Method of disinfecting carcasses: Animal carcasses are disinfected by applying to the surface of the animal carcass an acidified solution of chlorine dioxide. The chlorine dioxide solution should have a pH of about 2-3 and a concentration of 1-100 ppm. The contact time for the solution onto the carcass surface should be from about... Agent: Diversey, Inc.
20100272826 - Nano/macroporous bone tissue scaffolds for regenerative medicine: A biocompatible inorganic porous material having a three-dimensional coexistent network of interconnected macro-pores and nanopores produced by the steps of mixing an organic water-soluble polymer (e.g., polyethylene oxide or a block copolymer of ethylene oxide and propylene oxide), an alkoxysilane, and an inorganic water-soluble calcium salt in an aqueous acid... Agent: Saul Ewing LLP (harrisburg) Attn: Patent Docket Clerk
20100272827 - Method for transdermal iontophoretic delivery of chelated agents: Embodiments provide devices, systems and methods for the transdermal delivery of chelated compounds. One embodiment provides a method for the iontophoretic transdermal delivery of a chelated iron complex for the treatment of anemia. A first patch comprising an active electrode and a chelated iron complex is applied to the skin;... Agent: Bell & Associates
20100272828 - Silver-containing inorganic antibacterial: b
20100272829 - Composition for transdermal or transmucosal administration:
20100272830 - Biocide combination for use in agricultural applications: The invention is directed to a combination characterised by a high biocide power for use in agricultural applications, comprising a sodium or potassium hypochlorite solution and an agent allowing to generate hypochiorous acid at the moment of the application, adjusting the concentration thereof in a simple way.... Agent: Eschweiler & Associates, LLC National City Bank Building
20100272832 - Topical compositions for anti-aging and methods of using same: A pharmaceutical composition for treatment of skin aging including a pharmaceutically effective amount of estriol; a pharmaceutically effective amount of estradiol; a pharmaceutically effective amount of hyaluronic acid; a pharmaceutically effective amount of green tea extract; and a pharmaceutically acceptable carrier is provided. In some embodiments, the composition further includes... Agent: Knobbe Martens Olson & Bear LLP
20100272833 - Topical compositions for anti-aging and methods of using same: A pharmaceutical composition for treatment of skin aging including a pharmaceutically effective amount of estriol; a pharmaceutically effective amount of estradiol; a pharmaceutically effective amount of hyaluronic acid; a pharmaceutically effective amount of green tea extract; and a pharmaceutically acceptable carrier is provided. In some embodiments, the composition further includes... Agent: Knobbe Martens Olson & Bear LLP
20100272834 - Freeze-dried molded article containing magnesium ascorbyl phosphate: The invention relates to freeze-dried molded articles containing magnesium ascorbyl phosphate and alginate as well as optionally one or more active substances and/or auxiliary substances. Furthermore, the invention relates to methods for manufacturing these freeze-dried molded articles, the combination of such freeze-dried molded articles in kit-of-parts arrangements together with aqueous... Agent: Dilworth & Barrese, LLP
20100272835 - Use of volatile oil from plants in preparing medicaments for preventing and treating diabetes: The use of plants or volatile oils thereof containing high d-Limonene in manufacturing medicaments for treatment of diabetes including type 2 diabetes and type 1 diabetes. Natural products above, as parent plants of d-Limonene, have effect to reduce blood glucose as strong as compound d-Limonene.... Agent: Gang Shu
20100272836 - Composition for increasing milk production containing artemisia capillaris: The present invention relates to a composition for increasing the milk production of livestock, containing Artemisia capillaris as an active ingredient. More specifically, relates to a composition and a feed additive for increasing the milk production of cows, containing Artemisia capillaris as an active ingredient, and a composition and a... Agent: Edwards Angell Palmer & Dodge LLP
20100272837 - Traditional chinese medicinal compositions for treating depression , formulation thereof, method for preparing the same thereof: The present invention relates to a traditional Chinese medicinal composition for treating depression, which has a significant therapeutic effect and comprises □as active components□ the traditional Chinese medicinal materials Fructus Gardeniae, Fructus Forsythiae, Rhizoma Pinelliae, and Cortex Magnoliae Officinalis. The present invention further concerns a method for the preparation of... Agent: Banner & Witcoff, Ltd.
20100272838 - Compositions comprising siraitia grosvenori extracts and methods for the treatment of infection: A method for the treatment and/or prophylaxis of a viral infection in a subject is provided wherein the method comprises the steps of providing a therapeutically effective amount of a composition comprising an extract of the fruit of Siraitia grosvenori Swingle and administering the composition to the subject. The fruit... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group
20100272839 - Treatment of fatty scalp with a lysate of bifidobacterium species: The present invention treats a fatty dandruff state of the scalp with a lysate of at least one microorganism of the genus Bifidobacterium species and/or a fraction thereof.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.10/21/2010 > patent applications in patent subcategories. categorized by USPTO classification
20100266490 - Metalloproteinase binding proteins: Proteins that bind to matrix metalloproteinase 14 and methods of using such proteins are described.... Agent: Lando & Anastasi, LLP
20100266491 - System for targeted delivery of therapeutic agents: The present invention provides a drug delivery system for targeted delivery of therapeutic agent-containing particles to tissues, cells, and intracellular compartments. The invention provides targeted particles comprising a particle, one or more targeting moieties, and one or more therapeutic agents to be delivered and pharmaceutical compositions comprising inventive targeted particles.... Agent: Pabst Patent Group LLP
20100266493 - Agonist antibodies against tshr: The invention provides antibodies that bind the thyroid stimulating hormone receptor (TSHR), especially in humans, and their uses in diagnostic and therapeutic roles. The invention also provides hybridomas for producing such antibodies.... Agent: Banner & Witcoff, Ltd.
20100266495 - Anti-cancer activity of an anti-thymidine kinase monoclonal antibody: Methods of diagnosing and treating cancers that overexpress thymidine kinase 1 on their cell surfaces are provided. These methods utilize monoclonal antibodies that bind specifically to thymidine kinase 1 to inhibit or prevent proliferation of the cancer cells.... Agent: Greenlee Sullivan P.C.
20100266496 - Anti-cd74 immunoconjugates and methods of use: Disclosed are compositions that include anti-CD74 immunoconjugates and optionally a therapeutic and/or diagnostic agent. In preferred embodiments, the immunoconjugates comprise one or more anti-CD74 antibodies or antigen-binding fragments thereof, conjugated to a carrier such as a polymer, nanoparticle, complex or micelle. Also disclosed are methods for preparing the immunoconjugates and... Agent: Immunomedics, Inc.
20100266497 - Internalizing anti-cd74 antibodies and methods of use: The present invention provides humanized, chimeric and human anti-CD74 antibodies, CD74 antibody fusion proteins, immunoconjugates, vaccines and bispecific that bind to CD74, the major histocompatibility complex (MHC) class-II invariant chain, Ii, which is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies, other malignancies in which... Agent: Immunomedics, Inc.
20100266498 - Nucleic acid and corresponding protein entitled 125p5c8 useful in treatment and detection of cancer: A novel gene (designated 125P5C8) and its encoded protein, and variants thereof, are described wherein 125P5C8 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 125P5C8 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 125P5C8 gene... Agent: Agensys C/o Morrison & Foerster LLP
20100266494 - Treatment of cancer with novel anti-il13 monoclonal antibodies: The present invention relates to the treatment of IL13 dependent neoplastic disorders comprising the administration of novel anti-IL13 antibodies. The invention also includes diagnosing such tumors or cancer using the antibodies of the present invention to detect overexpression of IL13 in the patient.... Agent: Nikolaos C. George Jones Day
20100266499 - Cytokine receptor zcytor17 multimers: Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17-containing multimeric or heterodimer cytokine receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and... Agent: Zymogenetics, Inc. Intellectual Property Department
20100266500 - Stilbene derivatives and their use for binding and imaging amyloid plaques: This invention relates to a method of imaging amyloid deposits and to labeled compounds, and methods of making labeled compounds useful in imaging amyloid deposits. This invention also relates to compounds, and methods of making compounds for inhibiting the aggregation of amyloid proteins to form amyloid deposits, and a method... Agent: Woodcock Washburn LLP
20100266501 - Methods and compositions for organ protection: The invention relates in some aspects to compositions that include a contrast agent and an antioxidant compound and the use of such compositions to prevent (e.g., reduce) organ damage in a subject. In some aspects, the invention relates to compositions that include N— acetylcysteine (NAC) and a contrast agent and... Agent: Wolf Greenfield & Sacks, P.C.
20100266502 - Pharmaceutical composition comprising anti-hb-egf antibody as active ingredient: An anti-HB-EGF antibody having an internalizing activity is disclosed. A cytotoxic substance is preferably bound to the anti-HB-EGF antibody of the present invention. Also provided are an anti-cancer agent and a cell proliferation inhibitor, which comprise the antibody of the present invention as an active ingredient, a method of treating... Agent: Davidson, Davidson & Kappel, LLC
20100266503 - Breast cancer methods, medicaments and agents: A method of combating breast cancer in a mammalian individual, the method comprising administering to the individual an agent which reduces the function of the gamma secretase (GS) complex.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.
20100266504 - Condensed pyridine derivative and use thereof: m
20100266505 - Immunotherapy regimes dependent on apoe status: The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered to a patient depends on the ApoE genotype of the patient.... Agent: Townsend And Townsend And Crew, LLP
20100266508 - Stabilized gold nanoparticle and contrast agent: A kit for providing a contrast enhancer in a mammal for contrasting during imaging of the mammal comprises functionalized gold nanoparticles configured to be directed to one or more of a target organ, tissue and lesion of the mammal.... Agent: Greer, Burns & Crain
20100266506 - Flourescent dendrimer compounds and use of such compounds in multi-photon devices or processes: Fluorescent chemical compound composed of an n-generation dendrimer, n being a non-zero integer, exhibiting: -at least one central nucleus (N) with a valency of m, selected from the group consisting of -at least one first, non-chromophoric unit (X) with a valency of m′, and -at least one second unit (Y)... Agent: Thomas, Kayden, Horstemeyer & Risley, LLP
20100266507 - Luminescent compounds: where B—Z—C is a reporter molecule based on a cyanine, squaric acid, or other reporter, and K is a macrocycle that encircles and interlocks with the reporter molecule. Applications of the reporter compounds are provided, as well as reactive intermediates used to synthesize the reporter compounds, and methods of synthesizing... Agent: James R. Abney Kolisch Hartwell, P.C.
20100266510 - Foamable vehicle and pharmaceutical compositions thereof: A hygroscopic pharmaceutical composition includes at least one hygroscopic substance at a concentration sufficient to provide an Aw value of at least 0.9 and an antiinfective agent. A foamble pharmaceutical carrier includes about 50% to about 98% of a polar solvent selected from the group consisting of a polyol and... Agent: Wilmerhale/boston
20100266509 - Heteroaryl amide analogues as p2x7 antagonists: Heteroaryl amide analogues are provided, of Formula (I), wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion... Agent: Lundbeck Research Usa, Inc. Attention: Stephen G. Kalinchak, Legal
20100266512 - Crosslinked hyaluronic acid in emulsion: The present invention relates to methods of producing crosslinked hyaluronic acid microbeads, as well as the produced microbeads, said method comprising the steps of: (a) providing an aqueous alkaline solution comprising hyaluronic acid, or a salt thereof; (b) forming microdroplets having a desired size from the mixed solution of step... Agent: Scully Scott Murphy & Presser, PC
20100266511 - Pharmaceutical foam: The present invention provides various pharmaceutically active topical delivery compositions. In particular, compositions of the present invention are present in a pressurized container comprising a quick-breaking alcoholic foaming agent, such that when the composition is released, i.e., dispensed, from the pressurized container, a quick-breaking temperature sensitive foam is formed. In... Agent: Glaxo Smith Kline C/o The Nath Law Group
20100266513 - Amphiphilic polymeric material: The present invention concerns an amphiphilic polymeric material which comprises a straight or branched chain carbon-carbon backbone and a multiplicity of side chains attached to the backbone, wherein the side chains have formula (I). At least one of R1 and R2 is the group —C(O)Q; wherein Q comprises a hydrophilic... Agent: Oliff & Berridge, PLC
20100266514 - Dual component dental composition containing enzyme: A two component desensitizing dentifrice composition is disclosed which comprises a first dentifrice component containing an enzyme such as papain and a second dentifrice component containing an ionic surfactant such as sodium lauryl sulfate, the first and second dentifrice components being maintained separate from the other until dispensed for application... Agent: Colgate-palmolive Company
20100266515 - Treatment of malodour: This invention relates to methods for inhibiting growth of anaerobic bacteria, particularly halitosis causing bacteria. The methods use BLIS-producing Streptococcus salivarius strains, extracts thereof, and compositions comprising same in the prevention or treatment of halitosis.... Agent: Frommer Lawrence & Haug
20100266516 - Personal care composition: An aqueous shear-thinning personal care composition comprises: (a) at least 3 wt % of a sulfonate compound of general formula (I): where R1 represents a C8-22 alkyl group alkyl group; R2 represents a C1-4 alkyl group; each of R3, R4 and R5 independently represents a hydrogen atom or a C1-4... Agent: Burns & Levinson, LLP
20100266517 - Two-coat cosmetic compositions: Two-coat compositions and methods are provided for forming cosmetic films on a biological surface which are long-lasting, transfer-resistant, water-proof, oil-proof, non-migrating, comfortable to wear, and which are capable of filling in fine lines and wrinkles. The two-coat compositions generally comprise a hydrophilic base coat composition and a top coat composition,... Agent: Avon Products, Inc.
20100266519 - Production method of a powder cosmetic: The present invention is to provide an easy production method of powder cosmetics having improved practical characteristics such as extensibility on the skin, adhesion, feeling of particulate fineness, and long-lasting property, and having improved impact resistance. A production method of a powder cosmetic comprising; mixing powder component and oil component... Agent: Rankin, Hill & Clark LLP
20100266520 - Cosmetic composition comprising a semicrystalline polyurethane/polyester copolymer: The present invention relates to a cosmetic composition including, in a physiologically acceptable medium, an effective quantity of at least one semicrystalline polyurethane/polyester copolymer and at least one dye substance, the copolymer having a melting point greater than or equal to 20° C.... Agent: Oliff & Berridge, PLC
20100266521 - Stabilized cationic ammonium compounds and compositions comprising the same: Stabilized cationic ammonium compounds are described. The compounds are stabilized with metal chelators that impede the generation of nitrogen comprising groups from the cationic ammonium compounds.... Agent: Unilever Patent Group
20100266523 - Compositions containing flavanoid polyphenol derivatives, and applications thereof in controlling diseases and ageing of living organisms: The invention relates to compositions of polyphenol derivatives, characterised in that said polyphenols contain monomers, oligomers or polymers of units of the formula (I), wherein said units are characterised by the simultaneous presence of a phloroglucinol-type core (core A) and of a catechol-type core (core B) bonded together by a... Agent: Nixon & Vanderhye, PC
20100266522 - Petrolatum based composition comprising greater than 10% silicone for improved feel while remaining stable: The present invention discloses petrolatum based composition containing silicone oils which are structured with specific blend and ratio of fatty acids.... Agent: Unilever Patent Group
20100266524 - Composition comprising silicone oil or oils structured with compolymers carrying greater than 70% long chain alkyl group: The present invention discloses silicone oils which are structured with a copolymer comprising a large percentage of alkane groups. Using high percentage pendant alkane helps provide silicone with ideal gel properties (G′>G″, particularly >1000 cP, more preferably 2000-30,000 cP) and viscosity, after fracture, of 10 to 1000 cP, preferably 30-500... Agent: Unilever Patent Group
20100266525 - Method for removing microbes from surfaces: A method has been found for the removal of microbial biofilm on surfaces in contact with systems, including but not limited to aqueous systems, which comprises adding to the aqueous system an effective amount of a carbosilane-based surfactant to substantially remove microbial biofilm, from surfaces in aquatic systems, while presenting... Agent: General Electric Company Ge Global Patent Operation
20100266526 - Combination therapy for treating hypercholesterolemia: The invention further relates to pharmaceutical compositions useful for the treatment of hypercholesterolemia and atherosclerosis, and for reducing serum cholesterol. The pharmaceutical compositions comprise a combination of a first amount of an unsubstituted polydiallylamine polymer compound and a second amount of a cholesterol-lowering agent. The first and second amounts comprise... Agent: Hamilton, Brook, Smith & Reynolds, P.C.
20100266527 - Anti-microbial polymers and their compositions: Polymers derived directly from acrolein monomer that are substantially soluble in water and/or aqueous media, together with methods for preparing same and compositions containing such for use as an anti-microbial, anti-cancer, anti-inflammatory and/or anti-coagulant.... Agent: Frommer Lawrence & Haug
20100266529 - Derivatives of growth hormone and related proteins, and methods of use thereof: The growth hormone supergene family comprises greater than 20 structurally related cytokines and growth factors. A general method is provided for creating site-specific, biologically active conjugates of these proteins. The method involves adding cysteine residues to non-essential regions of the proteins or substituting cysteine residues for non-essential amino acids in... Agent: Sheridan Ross PC
20100266528 - Systemic administration of colony stimulating factors to treat amyloid associated disorders: The invention relates a method of treating amyloidosis, diseases and disorders associated with amyloid plaque formation, e.g., Alzheimer's disease by increasing tissue resident macrophage activity in an organ or tissue of an animal requiring treatment by systemic administration of a colony stimulating factor. For example, the activity of bone marrow-derived... Agent: Sterne, Kessler, Goldstein & Fox, P.l.l.c.
20100266535 - Compounds having crth2 antagonist activity: e
20100266533 - Death domain containing receptors: The present invention relates to novel Death Domain Containing Receptor (DR3 and DR3-V1) proteins that are members of the tumor necrosis factor (TNF) receptor family. In particular, isolated nucleic acid molecules are provided encoding the human DR3 and DR3-V1 proteins. DR3 and DR3-V1 polypeptides are also provided, as are vectors,... Agent: Human Genome Sciences Inc. Intellectual Property Dept.
20100266530 - Fcrn antibodies and uses thereof: In certain embodiments, this present invention provides polypeptide compositions (e.g., antibodies and antigen binding portions thereof that bind to FcRn), and methods for modulating FcRn activity. In other embodiments, the present invention provides methods and compositions for treating autoimmune disorders.... Agent: Ropes & Gray LLP
20100266534 - Human lymphocyte vaccine adjuvant: The present invention relates to an adjuvant derived from human lymphocytes. The adjuvant can be used in combination with traditional vaccines or cancer immunotherapy, to enhance the response of the patient's immune system to the vaccine or other immunotherapeutic agent. The adjuvant is derived from the supernatant collected from cultured... Agent: Thompson Hine L.L.P. Intellectual Property Group
20100266531 - Il-17 binding proteins: Proteins that bind IL-17 and/or IL-17F are described along with there use in composition and methods for treating, preventing, and diagnosing IL-17 related diseases and for detecting IL-17 in cells, tissues, samples, and compositions.... Agent: Yankwich & Associates, P.C. (and Abbott Bioresearch Center)
20100266532 - Methods for inhibiting scarring: The invention provides new methods of treatment using anti-scarring agents to inhibit scarring in humans, and also provides anti-scarring agents for new uses in the inhibition of scarring in humans. In a first incidence of treatment an anti-scarring agent is provided to each centimetre of a wound margin or each... Agent: Foley And Lardner LLP Suite 500
20100266536 - new type of consensus interferon and preparation method thereof: The invention relates to variants of consensus interferon protein with improved properties, such as improved anti-viral activity, and use thereof. The variants are also easier to renature after denaturant treatment. The invention also relates to the preparation method of the variants consensus interferon.... Agent: Morgan, Lewis & Bockius, LLP (sf)
20100266539 - Chemokine receptor antagonist and medical use thereof: The compound represented by formula (I) has chemokine receptor (especially in CCR4 and/or CCR5) antagonistic activity. Therefore it is useful for prevention and/or treatment of a chemokine receptor-mediated disease such as inflammatory and/or allergic diseases [systemic inflammatory response syndrome (SIRS), anaphylaxis, anaphylactoid reaction, allergic angiitis, transplant rejection reaction, hepatitis, nephritis,... Agent: Sughrue-265550
20100266540 - Drug class for the treatment of cancer: Compositions, methods, and combination therapies for the treatment of cancers, including lymphomas, leukemias, melanomas, lung cancer, and metastatic disease, are provided. Specifically, compositions comprising ligands to Pgrmc1 are disclosed for use in treating and inhibiting tumor growth and progression and inhibition of metastases. The compositions and methods using these ligands... Agent: Crowell & Moring LLP Intellectual Property Group
20100266537 - Hcv inhibitors: The present invention is directed to compounds that are antiviral agents. Specifically the compounds of the present invention inhibit replication of HCV and are therefore useful in treating hepatitis C infections. The present invention is also directed to pharmaceutical compositions comprising these compounds and processes for preparing them.... Agent: Townsend And Townsend And Crew, LLP
20100266538 - Quinoxaline derivatives and their use for treating benign and malignant tumour disorders: The invention provides quinoxalines of the general formula I which are used as medicaments preferably for treating tumour disorders, in particular in cases of drug resistance to other active compounds and in cases of metastasic carcinoma. The possible applications are not limited to tumour disorders.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.
20100266543 - Linked dibenzimidazole antivirals: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a... Agent: Elmore Patent Law Group, PC
20100266541 - Methods and agents for modulating an immune response: This invention is directed to the targeting of proteins or peptides of interest to an autophagosome, for their presentation on a major histocompatibility complex (MHC) class II molecule and methods of use thereof. Nucleic acids, vectors comprising the same, and compositions for targeting proteins or peptides of interest to an... Agent: Fox Rothschild LLP Princeton Pike Corporate Center
20100266542 - Receptor coupling agents and therapeutic uses thereof: Receptor coupling agents, including multivalent constructs comprising anti-TNF receptor binding moieties, for treating cancer and inhibiting tumor volume in a subject are disclosed.... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000
20100266544 - Non-toxic crosslinking reagents to resist curve progression in scoliosis and increase disc permeability: A method of improving the resistance of collagenous tissue to mechanical degradation in accordance with the present invention comprises the step of contacting at least a portion of a collagenous tissue with an effective amount of a crosslinking reagent. Methods and devices for enhancing the body's own efforts to stabilize... Agent: Berliner & Associates
20100266548 - Lps-responsive chs1/beige-like anchor gene and therapeutic applications thereof: The present invention relates to a novel LPS-responsive and Beige-like Anchor gene (lrba), variants of the lrba gene, fragments of the lrba gene, and polypeptides encoded thereby. The subject invention also pertains to lrba interfering RNA, and uses thereof. In another aspect, the present invention also includes methods of inhibiting... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association
20100266547 - Methods and compositions for treatment of interferon-resistant tumors: The present invention provides a method for the treatment of interferon resistant tumors through the use of recombinant vectors encoding interferon species. In particular it is noted that interferon species provided by recombinant vectors possesses properties not associated with the recombinantly produced interferon proteins. The present invention further provides compositions... Agent: Townsend And Townsend And Crew, LLP
20100266545 - Obligately anaerobic mutant lactic acid bacterium and preparation method therefor, and expression vector functioning in obligately anaerobic lactic acid bacterium: The present invention provides an obligately anaerobic lactic acid bacterium having no risk of causing side effects in normal tissue and promising as a safe therapeutic agent and a gene transporter for a disease that is in an anaerobic environment such as a solid tumor, a preparation method therefor, and... Agent: Jones Day
20100266546 - Selectively replicating viral vectors: The present invention provides recombinant viruses which replicate the viral genome selectively in response to the intracellular conditions of the target cell through the use a pathway-responsive promoter which substantially inhibits viral replication in the host cell based on the phenotypic or genotypic of the infected cell. In the target... Agent: Townsend And Townsend And Crew, LLP
20100266549 - Novel probiotics for pet food applications: The present invention relates to novel lactic acid bacterial micro-organisms that have been isolated and selected for their probiotic potential and their use for the preparation of petfood compositions intended to improve the health of pets, and to compositions containing the same.... Agent: K&l Gates LLP
20100266550 - Mammalian milk microorganisms, compositions containing them and their use for the treatment of mastitis: The present invention relates to a novel approach to prevent or treat mastitis both in humans and animals through the use of mammal milk-derived microorganisms obtained from healthy hosts of the homologous species; to those new probiotic microorganisms obtained from milk able to reduce infectious mastitis and the method of... Agent: Moore & Van Allen PLLC
20100266560 - Agent stabilisation process and product: The invention relates to a composition and method of manufacture including a substrate coated with a biopolymer and aqueous biological gel and subsequently coated with at least one desiccation agent. The resulting composition is dry to touch, has a low water activity and stabilises the biological material for storage over... Agent: Sughrue Mion, PLLC
20100266551 - Adeno-associated viral vectors for the expression of dysferlin: The present invention relates to a composition comprising: a first adeno-associated viral (AAV) vector comprising: i) a 5′ITR (Inverted Terminal Repeat) sequence of AAV; ii) a portion of gene placed under the control of a promoter; iii) a sequence comprising a splice donor site; iv) a 3′ITR sequence of AAV;... Agent: Leason Ellis LLP
20100266558 - Method and assay for glycosylation pattern detection related to cell state of stem cells: A method and assay for characterizing populations of stem cells according to their glycosylation pattern, particularly for distinguishing between stem cell populations, for example with regard to state of differentiation.... Agent: Dr. D. Graeser Ltd.
20100266556 - Method for expanding hematopoietic stem cells using heterocyclic compound: A method for expanding hematopoietic stem cells and/or hematopoietic progenitor cells, which comprises culturing hematopoietic stem cells and/or hematopoietic progenitor cells ex vivo in the presence of a compound represented by the formula (I) (wherein X, Y, X, Ar1, R1, R2, R3, R4, R5, R6 and R7 are defined in... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.
20100266553 - Method for isolating and culturing adult stem cells derived from human amniotic epithelium: The present invention relates to a method for isolating and culturing adult stem cells derived from human amniotic membrane in high yield, and more particularly to a method for obtaining a large amount of adult stem cells, the method comprising obtaining amniotic epithelial cells from human amniotic tissue in high... Agent: Edwards Angell Palmer & Dodge LLP
20100266554 - Methods and composition for treating neural degeneration: Disclosed herein are methods and compositions for the use of marrow adherent stem cells and their descendents; e.g., bone marrow-derived neural regenerating cells; in the treatment of various neurodegenerative disorders. In certain embodiments, bone marrow-derived neural regenerating cells transplanted to sites of neural degeneration stimulate growth and/or survival of host... Agent: Robins & Pasternak
20100266555 - Micro rnas as markers of the functional state of a dendritic cell: The present invention relates to the use of specified micro RNAs as markers of the functional state of a dendritic cell. In one aspect the invention relates to a method for producing a quality-controlled therapeutic composition comprising dendritic cells. In another aspect the invention relates to a method of in... Agent: The Nath Law Group
20100266557 - Novel peptide-based scaffolds for cartilage regeneration and methods for their use: Disclosed herein are novel peptide amphiphile molecules and compositions composed of a peptide sequence that non-covalently binds the growth factor TGF-β1. Also disclosed are methods of using these peptide amphiphiles to create a gel scaffold in situ that enhances articular cartilage regeneration when used in combination with microfracture. Significant improvement... Agent: Nanotope, Inc. C/o Intellevate
20100266559 - Stabilized, sterilized collagen scaffolds with active adjuncts attached: Bioimplants and methods of making the bioimplants are provided. The bioimplants comprise biological tissues having conjugated thereto adjunct molecules. The biological tissues are sterilized with a chemical sterilizing agent, such as a water soluble carbodiimide. The processes of making the bioimplants include a process in which an adjunct molecule is... Agent: Intellectual Property Group Fredrikson & Byron, P.A.
20100266552 - Treatment of chronic lung disease: A method of cellular therapy for a lung disease or condition in a subject is disclosed, wherein the method involves the administration of multipotent epithelial stem cells derived from amnion tissue (AECs). In a particular application, the method is used for the treatment of lung diseases and conditions such as... Agent: Sheridan Ross PC
20100266561 - Recovery of tissue function following administration of b cells to injured tissue: The present invention relates generally to systems and methods of enhancing recovery of function of injured tissue through administration of a composition comprising a relatively pure populations of B lymphocyte cells in a pharmaceutically acceptable carrier to the injured tissue. Kits are provided to aid in purification of B cells... Agent: John S. Pratt, Esq Kilpatrick Stockton, LLP
20100266562 - Selective cytopheresis devices and related methods thereof: The present invention relates to systems and devices to treat and/or prevent inflammatory conditions within a subject and to related methods. More particularly, the invention relates to systems, devices, and related methods that sequester leukocytes and/or platelets and then inhibit their inflammatory action.... Agent: Casimir Jones, S.c.
20100266563 - Selective cytopheresis devices and related methods thereof: The present invention relates to systems and devices to treat and/or prevent inflammatory conditions within a subject and to related methods. More particularly, the invention relates to systems, devices, and related methods that sequester leukocytes and/or platelets and then inhibit their inflammatory action.... Agent: Casimir Jones, S.c.
20100266565 - Combinational chemotherapy treatment: Methods of combination chemotherapy that are effective for treating neoplasia are provided.... Agent: Dann, Dorfman, Herrell & Skillman
20100266564 - Polyunsaturated fatty acid synthase nucleic acid molecules and polypeptides, compositions, and methods of making and uses thereof: The present invention is directed to isolated nucleic acid molecules and polypeptides of thraustochytrid polyunsaturated fatty acid (PUFA) synthases involved in the production of PUFAs, including PUFAs enriched in docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), or a combination thereof. The present invention is directed to vectors and host cells comprising... Agent: Sterne, Kessler, Goldsein & Fox P.l.l.c
20100266568 - Ec sod and use thereof: The present invention relates to an EC SOD and the use thereof. More particularly, the present invention relates to an EC SOD and the use thereof for preventing or treating skin diseases, particularly dermatitis or psoriasis.... Agent: Edwards Angell Palmer & Dodge LLP
20100266566 - Treatments involving glutaredoxins and similar agents: The present invention generally relates to treatments involving glutaredoxins. In one aspect, systems and methods of the invention can be used to treat a subject having an oxidative stress condition, for example, airway inflammation or asthma. In some embodiments, a glutaredoxin may be used to treat a subject. Also provided... Agent: Wolf Greenfield & Sacks, P.C.
20100266567 - Use of urate oxidase for the treatment or prophylaxis of disorders or indirect sequelae of the heart caused by ischemic or reperfusion events: The invention relates to the use of a urate oxidase, preferably recombinant urate oxidase, for example rasburicase, for the treatment or prophylaxis of disorders or indirect sequelae of the heart caused by ischemic or reperfusion events, for example during and after cardiac surgery like CABG (coronary artery bypass graft), PCI... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC
20100266570 - Dimeric derivatives of artemisinin and application in anticancer therapy: The present invention relates to dimeric derivatives of 10-trifluoromethylated artemisinin of formula (I): or a pharmaceutically acceptable salt thereof with B1 and B2 selected from C═O, CHOH and CH2, as well as to their use in treating cancer and to their preparation method.... Agent: Birch Stewart Kolasch & Birch
20100266569 - Prostatic acid phosphatase for the treatment of pain: Methods and compositions are provided for the treatment of pain and cystic fibrosis. The methods include administering to an animal a composition or a pharmaceutical formulation comprising a therapeutically effective amount of a Prostatic Acid Phosphatase (“PAP”) polypeptide, or an active variant, fragment or derivative thereof, or a therapeutically effective... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.
20100266571 - Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones: The present invention provides dosing regimens for administering pharmacological chaperones to a subject in need thereof. The dosing regimens can be used to treat disorders caused by improper protein misfolding, such as lysosomal storage disorders.... Agent: Hoffmann & Baron, LLP
20100266572 - Treatment and prevention of ischemic injury using activated protein c: Methods and compositions are provided for treating or preventing ischemic injury in a tissue flap in order to reduce the incidence of flap necrosis. Some compositions comprise one or more of an activated protein C (APC), a functional fragment of an APC, an APC mimetic compound, and a derivative of... Agent: Fenwick & West LLP
20100266573 - Method and means for obtaining bronchorelaxation: A method for producing bronchorelaxation in a human or an animal affected by airway obstruction comprises administration of a pharmacologically effective amount of elemental iodine on activated charcoal (iodinated activated charcoal) to the intestine of said human or animal. A pharmaceutical composition comprising elemental iodine on activated charcoal and uses... Agent: Dickstein Shapiro LLP
20100266577 - Method of cancer treatment with antagonists of fas inhibitors: In one embodiment, the present invention relates to a method of treating a cancer characterized by inhibition of Fas-mediated apoptosis, comprising administering to a patient suffering from the cancer a pharmaceutically-effective amount of a composition comprising a peptide that competitively antagonizes at least one protein-Fas binding selected from the group... Agent: Williams, Morgan & Amerson
20100266574 - Oligoribonucleotides and methods of use thereof for treatment of fibrotic conditions and other diseases: The invention relates to a double-stranded compound, preferably an oligoribonucleotide, which down-regulates the expression of a gene of the TGase family at post-transcriptional level. The invention also relates to a pharmaceutical composition comprising the compound, or a vector capable of expressing the oligoribonucleotide, and a pharmaceutically acceptable carrier. The present... Agent: Cooper & Dunham
20100266575 - Soluble fms-like tyrosine kinase-1 (sflt-1) antibody and related composition, kit, methods of using, and materials and method for making: An isolated antibody that specifically binds to sFlt-1 or a fragment thereof having (i) a variable heavy domain region comprising the amino acid sequence of SEQ ID NO: 2, (ii) a variable light domain region comprising the amino acid sequence of SEQ ID NO: 4, or (iii) both (i) and... Agent: Paul D. Yasger Abbott Laboratories
20100266580 - Translocation and mutant tnk1 kinase in human lymphoma: In accordance with the invention, a novel gene translocation in human Hodgkin's lymphoma (HL) that results in a fusion protein combining part of C17ORF61 with Thirty-eight-negative kinase 1 (Tnk1) kinase has now been identified. The TNK1-C17ORF61 fusion protein, which retains TNK1 tyrosine kinase activity, was confirmed to drive the proliferation... Agent: Nancy Chiu Wilker, Ph.d. Chief Intellectual Property Counsel
20100266578 - Treatment and diagnostic methods for hypersensitive disorders: The current standard of care for the treatment of allergic airway diseases include short and long acting beta-agonists, and inhaled or systemic corticosteroids, cromolyn and xanthines that all have the potential of detrimental side-effects. The present invention describes a new mechanistic protein-based therapeutic approach for the treatment of allergic airway... Agent: Ropes & Gray LLP
20100266579 - Treatment of inflammatory diseases: We describe the involvement of JunD in the activation of macrophages and the association of JunD in inflammatory diseases and conditions.... Agent: Klarquist Sparkman, LLP
20100266576 - Use of a camelid single-domain antibody for detecting an oligomeric form of an amyloid beta peptide and its applications: Use of camelid single-domain antibodies for detecting an oligomeric form of the amyloid β peptide 42 and their therapeutic and diagnostic applications.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.
20100266581 - Compositions and methods for modulating s-nitrosogluthione reductase: Disclosed herein are methods and compositions for modulating the levels and/or activity of S-nitrosoglutathione reductase (GSNOR) in vivo or in vitro. Specifically disclosed are GSNOR deletion constructs, host cells and non-human mammals comprising GSNOR deletions, and methods of screening employing GSNOR deletion mutants. Also specifically disclosed are reagents and procedures... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c
20100266589 - Adjuvant cancer therapy: Disclosed herein are methods and compostions comprising anti-VEGF antibodies for use in adjuvant cancer therapy.... Agent: Genentech, Inc.
20100266584 - Antibodies against the ectodomain of erbb3 and uses thereof: The present invention provides a novel class of antibodies and antigen binding fragments thereof that bind the extracellular domain of ErbB3 receptor and inhibit various ErbB3 functions. For example, the antibodies and antigen binding fragments described herein are capable of binding to the receptor designated ErbB3 and inhibiting EGF-like ligand... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000
20100266588 - Breast cancer susceptibility gene gt198 and uses thereof: It has been discovered that the human GT198 gene (gene symbol PSMC3IP) at chromosome 17q21 acts as a tumor suppressor. The mutation of the GT198 gene causes the increased dominant negative splice variant activity and leads to the loss of wild type GT198 function, and in turn, induces breast and... Agent: Pabst Patent Group LLP
20100266587 - Compositions and methods to treat acute myelogenous leukemia: Compositions and methods for treating or preventing a hematologic malignancy, such as AML, using an anti-alpha4 antibody are described.... Agent: Lando & Anastasi, LLP B2047
20100266582 - Inhibition of il-17 production: The invention concerns inhibition of the production of proinflammatory cytokine interleukin-17 (IL-17) by T cells, using an antagonist of interleukin-23 (IL-23). The invention further concerns the use of IL-23 antagonists in the treatment of inflammatory diseases characterized by the presence of elevated levels of IL-17. IL-23 antagonists include, without limitation,... Agent: Arnold & Porter LLP (24126) Attn: Sv Docketing Dept.
20100266583 - Inhibition of il-17 production: The invention concerns inhibition of the production of proinflammatory cytokine interleukin-17 (IL-17) by T cells, using an antagonist of interleukin-23 (IL-23). The invention further concerns the use of IL-23 antagonists in the treatment of inflammatory diseases characterized by the presence of elevated levels of IL-17. IL-23 antagonists include, without limitation,... Agent: Arnold & Porter LLP (24126) Attn: Sv Docketing Dept.
20100266585 - Monoclonal antibodies specific to hemagglutinin and neuraminidase from influenza virus h5-subtype or n1-subtype and uses thereof: Monoclonal antibodies and related binding proteins that bind specifically to the envelope glycoprotein of H5 subtypes or neuraminidase glycoprotein of N1 subtypes of avian influenza virus (AIV) are provided. The monoclonal antibodies and related binding proteins are useful for the detection of H5 and N1 subtypes of AIV, including H5N1... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.
20100266586 - Variable antibodies: The present invention discloses inhibitory antibodies against Factor VIII with modified glycosylation, either by enzymatic deglycosylation or by site directed mutagenesis. Said antibodies with modified glycosylation have equal affinity for FVIII but show different inhibiting properties. The use of one or a mixture of said antibodies allow modulation of the... Agent: Nixon & Vanderhye, PC
20100266590 - Combination therapy: e
20100266591 - Method of treating erythropoietin hyporesponsive anemias: The invention relates to methods of using compositions comprising EPO-mimetic peptides to treat anemia. The invention relates to methods of treating disorders characterized by the insufficient amounts of erythrocytes and hemoglobulin in the blood due to myelodysplastic syndrome (MDS) or by hemoglobinopathies, such as alpha- or beta-thalessemia or sickle cell... Agent: Philip S. Johnson Johnson & Johnson
20100266592 - Therapeutic antennapedia-antibody molecules and methods of use thereof: The present invention is based on the seminal discovery that an antibody or fragment thereof combined with Antennapedia or a fragment thereof, is an effective therapeutic agent. The invention describes the construction of antibody or antibody fragment fused or chemically conjugated with Antennapedia at its carboxyl or its amino terminus... Agent: Dla Piper LLP (us)
20100266593 - Wnt antagonists and their use in the diagnosis and treatment of wnt-mediated disorders: The present invention provides for chimeric Wnt antagonists comprising a Frz domain component derived from a Frizzled protein, a secreted Frizzled related protein or Ror protein and an Fc immunoglobulin component, and their use in the treatment and diagnostic detection of cellular Wnt signaling and Wnt-mediated disorders, including cancer.... Agent: Genentech, Inc.
20100266594 - Il-9 in fibrotic and inflammatory disease: The present invention encompasses methods of employing inhibitors of IL-9 in the treatment of fibrotic disorders, e.g., COPD and inflammatory bowel disease.... Agent: Medimmune, LLC Patrick Scott Alban
20100266595 - Treatment of insulin-resistant disorders: The invention concerns the treatment of insulin-resistant disorders. In particular, the invention concerns the treatment of insulin-resistant disorders by administration of IL-17, such as IL-17A and/or IL-17F antagonists, such as anti-IL-17A and/or IL-17F and/or IL-17Rc antibodies, or antibody fragments.... Agent: Arnold & Porter LLP (24126) Attn: Sv Docketing Dept.
20100266596 - Therapeutic antibody purification method and method of use: A method of preparing anti-b amyloid immunoglobulin involves treating human plasma anti-b amyloid immunoglobulin under alkaline conditions, such as at pH 10.25 to 11.75 using diethylamine HCl, to dissociate b amyloid protein therefrom. Typically, the anti-b amyloid immunoglobulin is present in human immunoglobulin preparations obtained from plasma or serum. Anti-b... Agent: Foley And Lardner LLP Suite 500
20100266601 - Antibodies that inhibit tslp activity: The invention is directed to purified and isolated novel TSLP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above.... Agent: Immunex Corporation Law Department
20100266597 - Cytokine receptor zcytor17 multimers: Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17-containing multimeric or heterodimer cytokine receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and... Agent: Zymogenetics, Inc. Intellectual Property Department
20100266599 - Human receptor proteins; related reagents and methods: Nucleic acids encoding mammalian Toll-like receptors (TLRs) have been identified in human cells. Recombinantly produced TLRs are used in the preparation of antibodies that are capable of binding to the TLRs. The antibodies are advantageously used in the prevention and treatment of septic shock, inflammatory conditions, and viral infections.... Agent: Merck Patent Department (k-6-1, 1990)
20100266600 - Methods of using il-31 antagonists in diseases mediated by cutaneous lymphocyte antigen positive t cells: The present invention relates to predicting therapeutic response of treating patients suffering from itching and puritis mediated by cutaneous lymphocyte antigen positive T cells in atopic dermatitis. The invention also includes methods of predicting a therapeutically responsive patient population.... Agent: Zymogenetics, Inc. Intellectual Property Department
20100266598 - Peptide that elicits neutralizing antibodies targeting the hiv co-receptor, ccr5: The present invention relates, e.g., to an isolated peptide comprising a sequence of contiguous amino acids that is at least about 60% identical (e.g., at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or 100% identical) to the sequence E-W-Q-K-E-G-L-V-T-L-W-L (SEQ ID NO:1), or an active variant... Agent: Ott-nih C/o Edwards Angell Palmer & Dodge LLP
20100266602 - Method for diagnosing rheumatoid arthritis via assaying myofibroblast-like synoviocytes for fibroblast activation protein: The invention relates to methods for diagnosing rheumatoid arthritis by assaying for Fibroblast Activation Protein Alpha expression in rheumatoid, myofibroblast like synoviocytes. Therapeutic aspects are also a part of the invention.... Agent: Fulbright & Jaworski, LLP
20100266603 - Monoclonal antibody specific to ochratoxin a: This invention provides a monoclonal antibody specific to ochratoxin A and methods of assaying the level of ochratoxin A in food and feed.... Agent: Wpat, PC Intellectual Property Attorneys
20100266604 - Use of tam receptor inhibitors as immunoenhancers and tam activators as immunosuppressors: This disclosure concerns compositions and methods for immunoenhancement and/or immunosuppression. In certain embodiments, the disclosure concerns methods of using a TAM receptor inhibitor for immunoenhancement, for example as a vaccine adjuvant, for the treatment of sepsis, or for treating an immunocompromised subject. Also disclosed are methods of screening for immunoenhancing... Agent: Klarquist Sparkman, LLP
20100266605 - Use of a cd28 binding pharmaceutical substance for making a pharmaceutical composition with dose-dependent effect: The invention relates to the use of a CD28-specific superagonistic monoclonal antibody (MAB) or of a mimetic compound of the same, for producing a pharmaceutical composition, wherein the dosage is below or above a defined dosage limit.... Agent: Mayer & Williams PC
20100266606 - Antibody therapy for highly pathogenic avian influenza virus: The present invention relates to a monoclonal antibody against hemagglutinin of highly pathogenic avian influenza virus subtype H5 or functional fragment thereof, a hybridoma producing the monoclonal antibody, and a composition comprising the monoclonal antibody or functional fragment thereof. In addition, the present invention relates to a method for preventing... Agent: Knobbe Martens Olson & Bear LLP
20100266607 - Antibody therapy for use in the digestive tract: In accordance with the invention, the development and use of antibodies within the digestive tract is provided. Antibodies are described that are used to treat disorders associated with altered permeability of the digestive tract. Antibodies are described with increased stability within the environment of the digestive tract. Antibodies are described... Agent: Elmore Patent Law Group, PC
20100266613 - Anti-tnf-alpha antibodies and their uses: The present invention relates to antibodies directed to the tumor necrosis factor alpha (“TNF-α”) and uses of such antibodies, for example to treat diseases associated with the activity and/or overproduction of TNF-α.... Agent: Dechert LLP
20100266609 - Antibody molecules which bind il-17a and il-17f: The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP
20100266610 - Auto-antibody markers of autoimmune disease: The present invention encompasses auto-antibodies associated with autoimmune disorders. The auto-antibodies may be used, for example, in methods of treating patients, methods of diagnosing patients, methods of monitoring disease progression of patients, and methods of prognosing patients.... Agent: Medimmune, LLC Patrick Scott Alban
20100266612 - Bmp-alk3 antagonists and uses for promoting bone growth: In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density and strength. In certain embodiments, the present invention provides ALK3 polypeptides, including ALK3-Fc fusion proteins.... Agent: Ropes & Gray LLP
20100266611 - Enhancement of immune responses by 4-1bb-binding agents: This invention features methods of enhancing immune responses in mammalian subjects and in vitro methods of enhancing the response of a T cell. Also embodied by the invention are methods of receiving and preventing the induction of energy in T cells.... Agent: Fish & Richardson P.C.
20100266608 - Il-17 antagonistic antibodies: An IL-17 binding molecule, in particular an antibody to human IL-17, more preferably a human antibody to human IL-17 is provided, wherein the hypervariable regions of the heavy and light chains have amino acid sequences as defined, for use in the treatment of a solid or hematological malignant diseases.... Agent: Novartis Corporate Intellectual Property
20100266614 - Ultra high affinity neutralizing antibodies: Ultra high affinity antibodies with binding affinities in the range of 1010 M−1, and even 1011 M−1 are disclosed. Such antibodies include antibodies having novel high affinity complementarity determining regions (CDRs), especially those with framework and constant regions derived from either humans or mice. Methods of preparing and screening such... Agent: Jones Day Medi
20100266617 - Antibodies to human programmed death receptor pd-1: Antibodies which block the binding of human Programmed Death Receptor 1(hPD-1) to its ligands (hPD-L1 or hPD-L2) and their variable region sequences are disclosed. A method of increasing the activity (or reducing downmodulation) of an immune response through the PD-I pathway is also disclosed.... Agent: Organon Usa, Inc. C/o Merck
20100266615 - D1-1 nucleic acids, polypeptides and related methods: The disclosure provides, among other things, novel angiogenesis-related nucleic acids, polypeptides and methods of use.... Agent: Mccarter & English, LLP Boston
20100266616 - Polypeptides, antibody variable domains and antagonists: The invention relates to anti-TNFR1 polypeptides and antibody single variable domains (dAbs) that are resistant to degradation by a protease, as well as antagonists comprising these. The polypeptides, dAbs and antagonists are useful for as therapeutics and/or prophylactics that are likely to encounter proteases when administered to a patient, for... Agent: Glaxosmithkline Global Patents -us, Uw2220
20100266618 - Compositions and methods for augmenting activity of oncolytic viruses: Disclosed are compositions and methods for augmenting activity of oncolytic viruses. Virus activity is augmented by sensitizing cancer or tumour cells through modulation of the Endoplasmic Reticulum (ER) stress response pathway, for instance by introducing into a tumour cell an agent effective to modulate ER stress response and sensitize the... Agent: David S. Resnick
20100266619 - Neutralizing antibodies and methods of use thereof: This invention provides monoclonal antibodies that recognize the Toll-like Receptor 4/MD-2 receptor complex, and monoclonal antibodies that recognize the TLR4/MD2 complex as well as TLR4 when not complexed with MD-2. The invention further provides methods of using the monoclonal antibodies as therapeutics. This invention also provides soluble chimeric proteins, methods... Agent: Mintz Levin Cohn Ferris Glovsky And Popeo, P.C.
20100266620 - Immunoconjugates for treatment of infectious diseases: The present invention features immunoconjugates which comprise therapeutic agents coupled to antibodies that specifically recognize pathogen surface antigens. These immunoconjugates can be used to treat or prevent infectious diseases. Upon administration of an immunoconjugate of the present invention to an infected host, the immunoconjugate binds to a specific antigen on... Agent: Winston & Strawn LLP Patent Department
20100266622 - Prevention and treatment of ocular side effects with a cyclosporin: Therapeutic methods are disclosed herein.... Agent: Allergan, Inc.
20100266623 - Synthetic, self adjuvanting vaccines: The present invention relates generally to the field of immunotherapy, and more particularly to immunomedicaments in the form of lipopeptides which induce an antibody response to drugs of dependence, and uses thereof in the treatment and prevention of drug addiction.... Agent: Knobbe Martens Olson & Bear LLP
20100266624 - Hepatitis-c virus testing: New styles of hepatitis C virus (HCV), referred to as HCV-3 and HCV-4, have been identified and sequenced. Antigenic regions of HCV-2, HCV-3 and HCV-4 polypeptides have been identified. Immunoassays for HCV and antibodies thereto are described, which allow more complete screening of blood samples for HCV, and allow HCV... Agent: Alston & Bird LLP
20100266626 - Adjuvanted glucans: The use of beta-glucans as antigens for immunising against fungi is known. According to the invention, the beta-glucans are administered together with an adjuvant. The adjuvant improves the immune response. The glucan will usually be conjugated to a carrier. Suitable glucans include laminarin and curdlan.... Agent: Novartis Vaccines And Diagnostics Inc.
20100266625 - Meningococcal and pneumococcal conjugate vaccine and method of using same: This disclosure relates to vaccine formulations comprising an immunogenic composition for inducing antibodies to both S. pneumoniae and N. meningitides in a subject. In a preferred aspect, the immunogenic composition comprises covalently conjugated recombinant PsaA (“rPsaA”) from S. pneumoniae and capsular polysaccharide from N. meningitidis serogroup C. This disclosure further... Agent: Fitch Even Tabin & Flannery
20100266627 - Allelic exchange mutagenesis in map: Particular aspects provide efficient allelic exchange methods to generate directed mutations within genes of slow-growing stains of mycobacteria (e.g., Mycobacterium avium subsp. paratuberculosis (Map), Map 10 or GFP-expressing Map K-10) using a phage-delivery system, and demonstrate high efficiency allelic exchange. Additional exemplary aspects provide non-naturally occurring slow-growing strains of mycobacteria... Agent: Davis Wright Tremaine, LLP/seattle
20100266629 - Cattle reproductive disease vaccines: The present invention relates to combination vaccines and methods for treating or preventing diseases or disorders in an animal caused by infection by Bovine Viral Diarrhea Virus (BVDV) Types 1 and 2, Bovine Herpes Virus Type-1 (BHV-1), Bovine Respiratory Syncytial Virus (BRSV), Parainfluenza Virus (PI3), Campylobacter fetus, Leptospira canicola, Leptospira... Agent: Pharmacia & Upjohn
20100266628 - Macrocyclic lactone combination compositions, vaccines and methods for producing same: An injectable composition, capable of preventing or controlling parasitic, viral, or bacterial infections or diseases, for example scours, in pregnant cows and viral infections or diseases in neonatal calves by parenterally administering to each cow in a herd of pregnant cows, a dose of a combination composition comprising: (a) at... Agent: Judy Jarecki-black, Ph.d., Esq. C/o Merial Ltd.
20100266631 - Compositions and methods for generating an immune response utilizing alphavirus-based vector systems: Compositions and methods are provided for Eukaryotic Layered Vector Initiation Systems and Alphavirus replicon particles for introducing heterologous sequences into cells for generating immune responses.... Agent: Novartis Vaccines And Diagnostics Inc.
20100266630 - Recombinant mva virus, and the use thereof: The present invention relates to recombinant vaccinia viruses derived from the modified vaccinia virus Ankara (MVA) and containing and capable of expressing foreign genes which are inserted at the site of a naturally occurring deletion in the MVA genome, and the use of such recombinant MVA viruses for the production... Agent: Law Office Of Salvatore Arrigo
20100266634 - Adjuvancy and immune potentiating properties of natural products of onchocerca volvulus: The present invention relates to a method for potentiating a specific immune response to an antigen in a mammal in need thereof. The method comprises administering to the mammal an effective amount of Ov-ASP, or at least one subunit of Ov-ASP, and an antigenic moiety.... Agent: K&l Gates LLP
20100266633 - Aids virus vaccines using sendai virus vector: The present invention provides a vaccine containing a Sendai virus vector encoding a virus protein of an immunodeficiency virus. By intranasally administering a Sendai virus encoding a virus protein of an immunodeficiency virus to a macaque monkey, the present inventors have succeeded in efficiently inducing protective immunity against an immunodeficiency... Agent: Clark & Elbing LLP
20100266635 - Hivcon: an hiv immunogen and uses thereof: The present invention provides artificial fusion proteins (AFPs) designed to elicit an anti-HIV immune response, as well as nucleic acid molecules and expression vectors encoding those proteins. The AFPs of the invention may comprise domains from various HIV proteins, such as Gag, Pol, Vif, and Env proteins, which are partial... Agent: Frommer Lawrence & Haug
20100266632 - Vaccine composition comprising an immunoadjuvant compound consisting of a rho gtpase family activator: An immunogenic or vaccine composition comprising an immunoadjuvant compound consisting of a Rho GTPase activator. The Activators of Rho GTPases, namely the cytotoxic necrotizing factor 1 (CNF1), and DNT bear immunostimulatory properties towards the systemic response to orally administered ovalbumine.... Agent: Young & Thompson
20100266636 - Method of conferring a protective immune response to norovirus: The present invention relates to vaccine compositions comprising Norovirus antigens and adjuvants, in particular, mixtures of monovalent VLPs and mixtures of multivalent VLPs, and to methods of conferring protective immunity to Norovirus infections in a human subject.... Agent: Cooley LLP Attn: Patent Group
20100266637 - Method of preventing early lawsonia intracellularis infections: The present invention relates inter alia to the use of a combination of a vaccine against Lawsonia intracellularis and an anti-Lawsonia antibiotic for the prevention or reduction of early, preferably fulminant Lawsonia intracellularis infections. The present invention relates particularly to the use of a live Lawsonia intracellularis vaccine in conjunction... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation
20100266638 - Headache treatment method: Herein disclosed are methods for treating headache, such as a chronic migraine for example, by administration of botulinum toxin to fixed specific locations of a patient at a fixed amount, as well as optionally administering additional botulinum toxin to a subset of the fixed specific locations of a patient to... Agent: Allergan, Inc.
20100266639 - Expression system: An immunogenic reagent which produces an immune response which is protective against Bacillus anthracis, said reagent comprising one or more polypeptides which together represent up to three domains of the full length Protective Antigen (PA) of B. anthracis or variants of these, and at least one of said domains comprises... Agent: John S. Pratt, Esq Kilpatrick Stockton, LLP
20100266640 - Plant-derived cholera and malaria vaccine: Described herein are methods for simultaneously immunizing a subject against Cholera and Malarial infection. Specifically exemplified herein are methods that involve administering compositions comprising a CTB-AMA1 or CTB-MSP1 derived from plants having plastids transformed to express such conjugates.... Agent: Timothy H. Van Dyke
20100266641 - Endophytic fungi from pteromischum sp. plant, compounds and methods of use: The present disclosure relates to endophytic fungi from higher plants such as a Pteromischum sp. plant, and to extracts and compounds from such fungi that have desirable biological activities, such as antifungal and immunosuppressive activities. The present disclosure further relates to compositions comprising such extracts and compounds, as well as... Agent: Suzannah K. Sundby (uc) Smith, Gambrell & Russell, LLP
20100266642 - Modified cells for targeted cell trafficking and uses thereof: This application provides methods of making modified cells containing pre-functionalized poly(ethylene glycol) (PEG) and/or other pre-functionalized polymers are provided. The modified cells produced according to the disclosed methods as well as their use in the treatment of various diseases are also provided.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association
20100266644 - Methods and compositions for administration of iron: The present invention generally relates to treatment of iron-related conditions with iron carbohydrate complexes. One aspect of the invention is a method of treatment of iron-related conditions with a single unit dosage of at least about 0.6 grams of elemental iron via an iron carbohydrate complex. The method generally employs... Agent: Sonnenschein Nath & Rosenthal LLP
20100266645 - Pharmaceutical compositions: Provided herein are formulations and methods for treating pain in human beings. Also provide are optimal ratios at which an opioid and an opioid antagonist may be combined for administration to humans such that the opioid activity is inhibited. These ratios may also be used to formulate compositions containing both... Agent: Patrick J. Halloran, Ph.d., J.d
20100266643 - Pulmonary and nasal delivery of serum amyloid p: The disclosure relates to methods for delivery of serum amyloid P to the respiratory system. Pharmaceutical compositions comprising SAP suitable for respiratory delivery are also provided.... Agent: Ropes & Gray LLP
20100266646 - Assemblies, systems, and methods for skin treatment incorporating oxidized cellulose: A refined oxidised cellulose (OC) material in various salt states having therapeutic treatments for skin. The micronized OC has a uniform particle size of the order of microns (0.001 to 0.050 mm). The OC is treated by further steps of oxidation, hydrolysis and refinement. The final product is chemically known... Agent: Ryan Kromholz & Manion, S.c.
20100266648 - Cosmetic compositions for imparting superhydrophobic films: Compositions and methods are disclosed for imparting super-hydrophobic properties to cosmetics, which can be used to significantly improve water repellency compared to traditional cosmetics. The compositions comprise a hydrophobic film former, and hydrophobic particles, in an emulsion base.... Agent: Avon Products, Inc.
20100266651 - Emulsifier including glycerin-modified organopolysiloxanes: The invention relates to emulsifiers comprising glycerin-modified organopolysiloxanes and to their use for the preparation of extraordinarily stable emulsions and dispersions.... Agent: Scully Scott Murphy & Presser, PC
20100266649 - Gel technology suitable for use in cosmetic compositions: A gel system comprising a fractal network of nanoparticles and macroscopic particles is disclosed. The gel system is capable of forming an “optical gel” effective to blurrfine lines and wrinkles as a consequence of the size domain differences between the fractal particles and the macroscopic particles. Cosmetic compositions comprising such... Agent: Avon Products, Inc.
20100266650 - Method of cosmetic care stimulating mitochondrial aconitase: g
20100266647 - Optical blurring pigment composition suitable for use in cosmetics: Compositions comprising a gel system made from a combination of a fractal network of nanoparticles and translucent macroscopic particles, titanium dioxide and other color pigments is disclosed. The compositions are capable of forming an effective film on the biological surface such as skin to blurring fine lines and wrinkles while... Agent: Avon Products, Inc.
20100266652 - Slow release biocidal thermoplastic compositions and articles: In one aspect, the invention is directed to a biocidal composition, comprising a mixture of a substantially oxidation-resistant thermoplastic polymer having a melting point of about 60° C. to about 100° C.; and a composition for releasing chlorine dioxide gas upon exposure to moisture and having a bulk density less... Agent: D.a. Stauffer Patent Services LLC
20100266653 - Biocidal polyacrolein composition: This invention relates to a biocidal composition comprising fine particles comprising polyacrolein wherein at least 90% of particles are of a size no more than 30 microns. Preferably at least 90% of particles are of size no more than 5 microns and still more preferably at least 90% of particles... Agent: Nixon Peabody LLP - Patent Group
20100266654 - Medical composition including an extracellular matrix particulate: Described are medical compositions including a collagenous ECM particulate dispersed in a carrier. Such medical compositions can be applied to at least a portion of a surface of a sheet of collagenous ECM material to form a medical product. Medical compositions and products as described herein find particular use in... Agent: Woodard, Emhardt, Moriarty, Mcnett & Henry LLP
20100266655 - Sustained delivery formulations of risperidone compounds: The present invention relates to a risperidone sustained release delivery system for treatment of medical conditions relating delusional psychosis, schizophrenia, bipolar disorder, psychotic depression, obsessive-compulsion disorder, Tourette syndrome, and autistic spectrum disorders. The sustained release delivery system includes a flowable composition containing risperidone, a metabolite, or a prodrug thereof and... Agent: Schwegman, Lundberg & Woessner, P.A.
20100266659 - Implantable devices formed on non-fouling methacrylate or acrylate polymers: Implantable devices formed of or coated with a material that includes a polymer having a non-fouling acrylate or methacrylate polymer are provided. The implantable device can be used for treating or preventing a disorder such as atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total... Agent: Squire, Sanders & Dempsey LLP
20100266658 - Osteogenic implants with combined implant materials and methods for same: Described are osteogenic implants that include a first implant material covered at least in part by a second implant material carrying an osteogenic protein such as a bone morphogenic protein. The first implant material can comprise a mineral and provide an inner scaffolding portion for supporting bone ingrowth, and the... Agent: Medtronic Attn: Noreen Johnson -IPLegal Department
20100266657 - Preformed drug-eluting device to be affixed to an anterior spinal plate: A drug-eluting device comprising a drug-eluting matrix containing at least one elutable drug, a method of manufacturing a preformed drug-eluting device, and an implant kit comprising the same.... Agent: Medtronic Attn: Noreen Johnson -IPLegal Department
20100266656 - Splittable elastomeric drug delivery device: A system for treating a vascular condition including a catheter and a splittable elastomeric drug delivery device. The splittable elastomeric drug delivery device includes a balloon disposed on the catheter. The balloon includes a first elastic layer and a second elastic layer. A therapeutic agent layer is disposed on at... Agent: Medtronic Vascular, Inc.IPLegal Department
20100266662 - Methods of promoting enhanced healing of tissues after cardiac surgery: Resorbable polylactide polymer healing membranes and methods of their applications are disclosed. In a broad embodiment, the invention features methods for inducing proper tissue healing after an open heart surgery. In one embodiment, the methods includes a step of forming a patch with a healing membrane over the open pericardium... Agent: Stout, Uxa, Buyan & Mullins LLP
20100266660 - Osteogenic implants with combined implant materials and methods for same: Described are osteogenic implants that include a first implant material covered at least in part by a second implant material carrying an osteogenic protein such as a bone morphogenic protein. The first implant material can comprise a mineral and provide an inner scaffolding portion for supporting bone ingrowth, and the... Agent: Medtronic Attn: Noreen Johnson -IPLegal Department
20100266661 - Osteogenic implants with combined implant materials and methods for same: Described are osteogenic implants that include a first implant material covered at least in part by a second implant material carrying an osteogenic protein such as a bone morphogenic protein. The first implant material can comprise a mineral and provide an inner scaffolding portion for supporting bone ingrowth, and the... Agent: Medtronic Attn: Noreen Johnson -IPLegal Department
20100266663 - Tissue-treating implantable compositions: A prosthesis for repairing a hernia includes an adhesion-resistant biodegradable region and an opposing tissue-ingrowth biodegradable region. When the prosthesis is implanted into the patient, the adhesion-resistant biodegradable region covers a fascial defect of the hernia, and the tissue-ingrowth biodegradable region is located above the adhesion-resistant biodegradable region while being... Agent: Stout, Uxa, Buyan & Mullins LLP
20100266664 - Devices and methods for ophthalmic drug delivery: Disclosed are ophthalmic drug-delivery devices, comprising a body having a proximal end and a distal end, wherein the body includes a styrene elastomer matrix and a drug in contact with the matrix. Also disclosed are methods of treating or preventing an eye disease in a subject, that involve contacting an... Agent: Alcon
20100266665 - Fenugreek flour for incorporating into food products: A process for obtaining fenugreek flour from fenugreek seeds has been developed, and the flour incorporated into baked or other food products. The processed fenugreek flour from boiled seeds was easier to add into food products than whole seeds and did not compromise the food's taste or texture. This fenugreek... Agent: Patent Department Taylor, Porter, Brooks & Phillips, L.l.p
20100266666 - Chewing gum tablet and method of dosing pharmaceutically active ingredients in such chewing gum tablet: A method of dosing pharmaceutically active ingredients in a compressed chewing gum tablet includes the steps of: providing one or more pharmaceutically active ingredients, mixing a chewing gum composition including the one or more pharmaceutically active ingredients and chewing gum granules, the chewing gum granules including gum base, and dosing... Agent: St. Onge Steward Johnston & Reens, LLC
20100266668 - Manufacturing dissolvable dosage forms: A method of manufacturing a dosage form is described wherein a liquid solution of a biologically compatible polymer containing a suspension of particulate material that is insoluble in the polymer is supplied to a liquid supply tube (2) having an outlet (2a) and an electrical field is established between the... Agent: Frost Brown Todd, LLC
20100266667 - Mucosal bioadhesive slow release carrier for delivering active principles: A mucosal bioadhesive slow release carrier comprising an active principle and devoid of starch, lactose, which can release the active principal for a duration of longer than 20 hours. This bioadhesive carrier contains a diluent, an alkali metal alkylsulfate, a binding agent, at least one bioadhesive polymer and at least... Agent: Birch Stewart Kolasch & Birch
20100266669 - Multi-zone films: The invention relates to single-layer oral disintegrating films having at least two distinct zones, which comprise nicotine and allow for effective buccal (=oral mucosal) absorption thereof.... Agent: Novartis Consumer Health, Inc.
20100266670 - Transdermally absorptive preparation: A percutaneous administration type pharmaceutical preparation in tape form comprising a flexible backing, which is not permeable by the active ingredient, and an adhesive base layer formed on said flexible backing; said adhesive base layer consisting essentially of an adhesive base material of acrylic copolymer, polyhydric alcohol and bisphosphonate or... Agent: Cheng Law Group, PLLC
20100266671 - Device and method for treating dermal tissue: The present disclosure provides gel compositions useful for treating the skin. The gel compositions are hydrogels that include from about 33 wt % to about 68 wt % of a humectant or a mixture of humectants; about 0 wt % to about 8 wt % of an electrolyte or mixture... Agent: Tyco Healthcare Group Lp
20100266678 - Cholesterol level lowering liposomes: Provided are methods of reducing cellular cholesterol levels using lipid particles that are capable of cellular entry. Such lipid particles may be used for treating or preventing a disease or condition that is caused by or associated with an increased cellular cholesterol level and for treating or preventing a disease... Agent: Foley And Lardner LLP Suite 500
20100266673 - Compositions and methods for the delivery of nitric oxide: H-NOX proteins are mutated to exhibit improved or optimal kinetic and thermodynamic properties for blood gas NO delivery. The engineered H-NOX proteins comprise mutations that impart altered NO or 02 ligand-binding relative to the corresponding wild-type H-NOX domain, and are operative as physiologically compatible mammalian blood NO gas carriers. The... Agent: Morrison & Foerster LLP
20100266679 - Crystalline modifications of n-alpha-(2,4,6-triisopropylphenylsulfonyl)-3-hydroxyamidino- (l)- phenylalanine 4-ethoxycarbonylpiperazide and/or salts thereof: The present invention relates to novel crystalline modifications of N-α-(2,4,6-triisopropylphenyl-sulfonyl)-3-hydroxyamidino-(L)-phenylalanine 4-ethoxy-carbonylpiperazide and/or salts thereof, which can be used as pharmaceutical agents, and to pharmaceutical compositions and pharmaceutical uses comprising these novel crystalline modifications.... Agent: Miles & Stockbridge PC
20100266674 - L-oddc prodrugs for cancer: The main drawback in the use of most nucleoside anticancer agents originates from their hydrophilic nature, of which property requires a high and frequent dosage for an intravenous administration. Unlike other nucleoside anti-tumor agents, troxacitabine appears to predominantly enter tumor cells by passive diffusion rather then by using nucleoside transporters,... Agent: Coleman Sudol Sapone, P.C.
20100266675 - Lipoproteins, lipopeptides and analogs, and methods for making and using them: The invention provides novel compositions—lipopeptides and analogs, including somocystinamide A, and somocystinamide A variants and analogs, and pharmaceutical compositions, liposomes and nanoparticles comprising them, and methods of making and using them. In one embodiment, these lipopeptides and analogs are used to induce apoptosis in a cell, which can be a... Agent: Joseph R. Baker, Apc Gavrilovich, Dodd & Lindsey LLP
20100266676 - Nanocapsules with a liquid lipid core charged with water-soluble or water-dispersible active agents: The invention relates to nanocapsules with a liquid lipidic core and a solid lipidic shell, the lipidic core being loaded with at least one water-soluble or water-dispersible ingredient, said ingredient being present in the form of a reverse micellar system.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.
20100266677 - Nucleic acid binding compounds and methods of use: The present invention relates to homo- and hetero-dimer compounds formed by a disulfide, sulfinyl thio, or olefin bond between two monomers. A method of making a homo- or hetero-dimer compound is also disclosed. The present invention also relates to monomer compounds capable of forming homo- or hetero-dimer compounds, as well... Agent: Nixon Peabody LLP - Patent Group
20100266680 - Treatment of cancer using tlr3 agonists: The present invention relates generally to the fields of genetics and medicine. More specifically, the present invention relates to improved methods of treating cancers using a TLR3 agonist, by assessing the expression of a TLR3 receptor by cancer cells.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association
20100266672 - Vaccines: The present invention provides a vaccine composition comprising the B subunit of Shiga toxin or an immunologically functional equivalent thereof which is able to bind the Gb3 receptor, complexed with at least one first antigen, and further comprising at least one second antigen (which may be the same or different... Agent: Glaxosmithkline Global Patents
20100266681 - Fatty acid alcohols: The present invention relates to a lipid composition comprising at least omega-3 polyunsaturated alcohols, or pro-drugs thereof, which omega-3 polyunsaturated alcohols, or pro-drugs thereof, comprising at least (all-Z)-5,8,11,14,17-eicosapentaen-1-ol, or pro-drug thereof, and (all-Z)-4,7,10,13,16,19-docosahexaen-1-ol, or pro-drug thereof, and their use as a pharmaceutical, in particular for the treatment of elevated triglyceride... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP
20100266682 - Polyethylene glycol-coated sodium carbonate as a pharmaceutical excipient and compositions produced from the same: Non-effervescent pharmaceutical compositions having at least one particle of carbonate coated by a layer of polyethylene glycol that substantially covers the at least one carbonate particle are described. Compositions are also described where the compositions include a weakly basic therapeutic agent, a first pH-modifying agent having at least one particle... Agent: O''melveny & Myers LLP Ip&t Calendar Department La-13-a7
20100266683 - New self emulsifying drug delivery system: n
20100266684 - Method and composition for administering an nmda receptor antagonist to a subject: The invention provides methods and compositions for administering an NMDA receptor antagonist (e.g., memantine) to a subject.... Agent: Wilson Sonsini Goodrich & Rosati Adamas Pharmaceuticals, Inc.
20100266685 - Seamless coated spherical filled capsules: Described is a spherical coated capsule comprising (a) a coating-free capsule having (i) a liquid or viscous core and (ii) a solid shell surrounding this core, and (b) a seamless, solid coating surrounding said coating-free capsule, wherein the diameter of the spherical coated capsule is in the greater than 9... Agent: Roylance, Abrams, Berdo & Goodman, L.L.P.
20100266686 - Anti-amyloid antibodies and their use in diagnosis and therapy of amyloid diseases: The invention concerns antibodies to amyloid fibrillar and non-fibrillar polypeptides. The invention further concerns the use of such antibodies in diagnosis, treatment and/or prevention of amyloid diseases. The present invention also provides preparations and methods for preventing and treating, in a mammal, a disease characterized by amyloid formation and/or aggregation,... Agent: Joyce Von Natzmer Pequignot + Myers LLC
20100266687 - Improved tablet coating: The present invention provides a tablet coating composition including a cellulose polymer, a plasticiser, a sweetener, and a powdered flavour composition. The powdered flavour composition includes a flavourant associated with a solid carrier. The present invention also provides a pharmaceutical tablet including a core containing an active agent and a... Agent: Occhiuti Rohlicek & Tsao, LLP
20100266688 - Anti-bacterial composition and method for producing the same: The invention discloses an anti-bacterial composition and method for producing the same. The anti-bacterial composition of the invention includes an organic siloxane material which comprises an amino group, and a plurality of silver atoms. Particularly, the organic siloxane material has a meshed structure, and the plurality of silver atoms are... Agent: Dr. Banger Shia Patent Office Of Bang Shia
20100266690 - Stabilizer concentrate for matrix compositions processed at elevated temperatures: A stabilizer concentrate of, by wt. (a) 5 to 50% of N-(trichloromethylthio)phthalimide, (b) 5-20% antioxidant, and optionally (c) a carrier component. The concentrate can be incorporated into a matrix composition, e.g., a plastic, and processed at temperatures up to 2800 C without degrading the biocide or discoloring the plastic.... Agent: International Specialty Products William J. Davis, Esq.
20100266689 - Tissue augmentation with active agent for wound healing: The invention relates to a bioactive settable hydrogel matrix having a pore creating material, which may also carry a therapeutic agent, and methods of using the same, for example, use in promoting internal wound healing, tissue repair, tissue regeneration.... Agent: Medtronic Attn: Noreen Johnson -IPLegal Department
20100266691 - Agents and methods to stimulate bone healing: An agent for stimulating bone healing including isolated lysophosphatidic acid (LPA) and a hydrogel. A method of enhancing bone healing including identifying a damaged area of a bone and administering an agent comprising lysophosphatidic acid (LPA) is administered to the damaged area of the bone. A method of increasing bone... Agent: Wells St. John P.s.
20100266693 - Controlled release local anesthetic comprising a biologically active non-sulfated glycosaminoglycan matrix: The invention relates to structuring a combination of bioactive materials that are capable of controlled extended release of local anesthesia lasting over 30 hours.... Agent: David Christopher Evans
20100266692 - Nanoparticles comprising a non-ionizable polymer and an anionic cellulosic polymer: A pharmaceutical composition comprises nanoparticles comprising a poorly water soluble drug, a poorly aqueous soluble non-ionizable polymer, and an anionic cellulosic polymer.... Agent: Chernoff, Vilhauer, Mcclung & Stenzel, LLP
20100266694 - Chitosan/carbon nanotube composite scaffolds for drug delivery: A novel composite for internal application within wounds, incisions, and the like, for the prevention of biofilm growth therein is provided. Such a composite includes an antibiotic introduced within a sponge-like chitosan delivery product with electrically conductive nanomaterials present. Such a delivery product is also lyophilized subsequent to nanomaterial introduction... Agent: Wyatt, Tarrant & Combs, LLP
20100266697 - Mixed ligand surface-modified nanoparticles: A composition comprises surface-modified nanoparticles of at least one amphoteric metal oxide or oxyhydroxide. The nanoparticles bear, on at least a portion of their surfaces, a surface modification comprising (i) at least one surface modifier selected from lactate, thiolactate, and mixtures thereof, and (ii) at least one surface modifier selected... Agent: 3m Innovative Properties Company
20100266695 - Multivalent clustering targeting strategy for drug carriers: The present invention provides clustered ligand vehicles for the delivery of a nucleic acid therapeutic agent to a target expressing a receptor. The invention further provides methods for treating a disease state by targeting a nucleic acid therapeutic agent to a target expressing a receptor using clustered ligand vehicles.... Agent: Townsend And Townsend And Crew, LLP
20100266696 - Organic compounds: A process of preparing a particulate and substantially crystalline drug substance. The process involves suspending a substantially crystalline drug substance in an anti-solvent to give a suspension, homogenising the suspension at elevated pressure to give drug particles that have a mean particle size of less than about 10 μm, and... Agent: Novartis Corporate Intellectual Property
20100266699 - Pharmaceutical suspensions and related methods: A pharmaceutical suspension having a therapeutically effective amount of phenylephrine and a therapeutically effective amount of a first active agent consisting essentially of a first substantially water insoluble active agent having an average particle size of between about 10 and about 100 microns, an effective amount of non-reducing sweetener; an... Agent: Philip S. Johnson Johnson & Johnson
20100266700 - Use of adsorbent carbon microspheres for the treatment of irritable bowel syndrome: Adsorbent carbon microspheres are administered to treat irritable bowel syndrome or symptoms associated with irritable bowel syndrome.... Agent: Knobbe Martens Olson & Bear LLP
20100266698 - Use of insulin for the treatment of cartilaginous disorders: The present invention relates to methods for the treatment and repair of cartilage, including cartilage damaged by injury or cartilaginous disorders, including arthritis, comprising the administration of insulin and/or insulin variants. Optionally, the administration may be in combination with a cartilage agent (e.g., peptide growth factor, catabolism antagonist, osteo-, synovial,... Agent: Genentech, Inc.
20100266701 - Anti-misuse microparticulate oral drug form: The invention relates to solid microparticulate oral dosage forms having a composition that prevents the misuse of the active pharmaceutical ingredient (API) contained therein. The aim of the invention is to prevent the improper use of solid oral drugs for any use other than the therapeutic use(s) officially approved by... Agent: Patton Boggs LLP
20100266703 - Novel powder and its method of manufacture: The invention relates to a novel powder, it's method of manufacture and the use thereof in powder material processing, particularly in the manufacture of components formed from compacted powder e.g. discs, monoliths, layers or tablets. The powders comprise coated host particles wherein over 70% of the mass of the powder... Agent: Rader, Fishman & Grauer PLLC
20100266704 - Octreotide depot formulation with constantly high exposure levels: The present invention relates to sustained release formulations comprising as active ingredient octreotide or a pharmaceutically-acceptable salt thereof and two different linear polylactide-co-glycolide polymers (PLGAs).... Agent: Novartis Corporate Intellectual Property
20100266702 - Particles containing an active agent in the form of a co-precipitate: The invention relates to particles containing an active agent in the form of a co-precipitate to a method for producing said particles and to pharmaceutical forms containing said particles.... Agent: Foley And Lardner LLP Suite 500
20100266705 - Nanoparticulate megestrol formulations: The present invention is directed to nanoparticulate compositions comprising megestrol. The megestrol particles of the composition have an effective average particle size of less than about 2000 nm.... Agent: Elan Drug Delivery, Inc. C/o Foley & Lardner
20100266706 - Oral particulate antitumor preparation: e
20100266707 - Method of treating cachexia with the removal or inactivation of macrophage inhibitory cytokine-1: A method of treating cachexia is disclosed involving the removal or inactivation of macrophage inhibitory cytokine-1 (MIC-1) present in the blood, plasma or serum of a cachexia subject. In one embodiment, the method comprises the steps of providing a suitable substrate for binding MIC-1 (e.g. a substrate provided with a... Agent: Nixon & Vanderhye, PC
20100266708 - Intra-mammary teat sealant formulation and method of using same to reduce or eliminate visual defects in aged cheeses: Described is an intra-mammary teat sealant and a corresponding method of forming a physical barrier in the teat canal of a non-human animal for prophylactic treatment of mammary disorders during the animal's dry period. The method includes the step of infusing a teat seal formulation including a metal salt in... Agent: Intellectual Property Dept./dewitt Ross & Stevens Wisconsin Alumni Research Foundation
20100266709 - Compositions and methods for treating burns: The present invention provides compositions and methods for treating burns comprising administering to a burn area of a subject in need thereof of a therapeutically effective amount of a composition comprising an anti-cytokine or anti-inflammatory agent or a functional derivative thereof; and a pharmaceutically acceptable excipient.... Agent: The Law Offices Of Andrew D. Fortney, Ph.d., P.C.
20100266710 - Pharmaceutical preparations comprising electrochemically activated hypochlorite solutions: The present application refers to pharmaceutical preparations comprising an active ingredient and a carrier wherein the carrier comprises an aqueous electrochemically activated salt solution.... Agent: Millen, White, Zelano & Branigan, P.C.
20100266711 - Thienobenzodiazepine modulators of d1 receptor, d2 receptor, and/or 5-ht2 receptor: The present invention relates to new thienobenzodiazepine modulators of D1 receptors, D2 receptors, and/or 5-HT2 receptors, pharmaceutical compositions thereof, and methods of use thereof.... Agent: Global Patent Group - Apx
20100266712 - Prevention of acute kidney injury: The present invention provides a method of attenuating or preventing acute kidney injury occurring in a subject following cardiac surgery involving cardio-pulmonary bypass. The method comprises administration of at least one agent which cause alkalinization of urine to the subject at a level effective to cause alkalinization of the subject's... Agent: Dla Piper LLP (us)
20100266713 - Aqueous ophthalmic compositions containing anionic therapeutic agents: The present invention is directed to the provision of multi-dose, ophthalmic compositions. The compositions possess sufficient antimicrobial activity to satisfy USP preservative efficacy requirements, as well as similar preservative standards (e.g., EP and JP). The compositions include a balance of ingredients that allow for the formation of ophthalmic compositions that... Agent: Alcon
20100266714 - P2x3 receptor antagonists for treatment of pain: The subject invention relates to novel P2X3 receptor antagonists that play a critical role in treating disease states associated with pain, in particular peripheral pain, inflammatory pain, or tissue injury pain that can be treated using a P2X3 receptor subunit modulator.... Agent: Merck
20100266715 - Composition for treating aids and associated conditions: An Aids and associated conditions related to Aids treating compositions is disclosed. The compositions comprise: a medicament selected from an extract of at least one of the following plant families: Apocynaceae (Pleioscarpa Bicarpellata); Annonaceae (Cleistopholis Patens); Dichapetalaceae (Dichapetehan Madagasca Riense); Annoceae (Uvaristrum Pierreanum); Cynocynaceae (Strophantus Gratus); Asclepiadaceae (Gongronema Latifolium); Combretaceae... Agent: Frommer Lawrence & Haug
20100266716 - Natural photodynamic agents and their use: The present invention is safe photodynamic agents and their use in treating microbial contamination.... Agent: William J Bundren The Law Office Of William J Bundren
20100266717 - Chemical and biological agents for the control of molluscs: Compositions and methods for controlling molluscs, members of the Gastropoda and Bivalvia classes which includes but is not limited to lactones, lactams, carbamates, amides, and/or carboxylic acid containing compounds as active ingredients and/or compounds derived from Pseudomonas and/or Erwinia. Also provided are methods and compositions for increasing the efficacy of... Agent: Cheryl H Agris Phd- None available for 10/01/2010
- None available for 10/7/2010
Previous industry: Chemistry of inorganic compounds
Next industry: Plastic article or earthenware shaping or treating: apparatus
RSS FEED for 20130509:
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.
Thank you for viewing Drug, bio-affecting and body treating compositions patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Drug, bio-affecting and body treating compositions patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Drug, bio-affecting and body treating compositions patents we recommend signing up for free keyword monitoring by email.
FreshPatents.com Support - Terms & Conditions
Results in 3.96798 seconds